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ETHANOL, CATECHOI.AMINES AND ALKALOIDS:
INTERFACE Of NEUROCHEMISTRY AND ALCOHOLISM
The theory has been advanced that tetrahydroisoquinoline (TIQ)
alkaloids may form in neuronal and chrornaffin cells during alcohol metabolism via condensation of catecholamines (CAs) and alcohol-derived
aldehydes.

The cyclic CA-type alkaloids could assume a physiological

role in the development of alcohol dependence (G.Cohen and M. Collins,
Science 167: 1749-1751).
As groundwork for in vivo studies on TIQs during alcoholism, the
following questions required study.
(1) What are suitable chronic alcoholic animal models for the
investigation of TIQ formation and CA changes?
(2) What are the possible products of catabolism of TIQs? Can the
catabolism of TIQs be blocked through methods similar to those used to
inhibit catabolism of endogenous amines?
(3) What pharmacological methods can be employed to maximize TIQ
formation in vitro and

i~ viv~?

What are the effects of these methods on

the enzymes of ethanol and acetaldehyde metabolism?
In the studies with chronic alcoholic animal models, mice and
rabbits were provided with liquid Metrecal/ethanol (EtOH) diets as the
sole sources of food.

This protocol produced intoxication and slight

alcohol withdrawal symptoms in the mice, agreeing somewhat with the
results of G. Freund (Arch. Neurol. 21: 315, 1969).
ii

Rabbits falMetrecal/

ethanol for 80 days displayed negligible signs of intoxication, despite
developing substantial blood EtOH and occasionally high blood acetaldehyde (AcD) concentrations.

Fatty liver changes were demonstrated.

Malnutritional aspects of this diet were possible factors contributing
to the pathologies seen.
4-Hydroxylated TIQ alkaloids derived from the neurotransmitter
NE and AcD or formaldehyde were found to be readily 0-methylated in
vitro in rat brain and liver homogenates.

Since it was significantly

inhibited by pyrogallol (PG; 1,2,3-trihydroxybenzene), the catechol
alkaloid 0-methylation was due in part to the same enzyme that catabolizes the endogenous CAs, catechol-0-methyltransferase (COMT).

Brain

COMT 0-methylated the TIQ alkaloids and NE to similar degrees, but liver
COMT 0-methylated the TIQs to a significantly greater extent than NE in
these experiments.

Furthermore, there was no evidence for monoamine

oxidase action on the cyclic alkaloids, although the open-chain NE precursor did produce oxidation products.
PG was found to have a novel effect on AcD and its metabolism.
Rats treated with PG prior to EtOH intoxication demonstrated significantly higher blood AcD levels than did non-PG-treated, intoxicated
controls.

It was determined in in vitro experiments that this effect

was due in part to PG inhibition of liver aldehyde dehydrogenase (ALDH).
Several other compounds structurally related to PG, notably the clinically-important decarboxylase inhibitor R044602 (for Parkinsonism
therapy), were found to inhibit ALDH iil vitro; this property may lead
these or similar trihydroxy-benzene-containing drugs to clinical application as disulfiram-like deterrents in human alcoholics.
Thus PG was found to be potentially useful in enhancing TIQ
iii

alkaloid levels in vivo through three biochemical mechanisms, two of
which were demonstrated in these studies: (1) Oxidation of AcD via ALDH
is inhibited and the concentration of one (AcD) of the two TIQ precursor
molecules is maximized.

(2) 0-Methylation (and possibly inactivation)

of TIQs is decreased, favoring the isolation of catechol TIQs by alumina
procedures currently in use.

(3) Combined with the well-established

inhibition of COMT by PG, which serves to maximize NE, epinephrine and
dopamine (precursors of TIQs), effects (1) and (2) should lead to detectable TIQ levels during intoxication.

In support of this, recent

studies by Bigdeli in this laboratory (M. Bigdeli, Ph.D. Dissertation,
Loyola University of Chicago, 1974) have shown that adrenal and brain
CA-derived TIQs are detectable by gas chromatography when EtOH-int&xicated rats are pretreated with PG.

iv
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--PA...1lT ONE
INTRODUCTION AND REVIEW OF THE LITERATURE
A. BACKGROUND
I.

THEORIES OF ALCOHOL DEPENDENCE
At present there is relatively poor consensus concerning an ad-

equate definition of alcoholism.

As with most diseases that are express-

ed primarily as behavioral disorders, many social and environmental factors affect the definition of the problem.

Perhaps the most widely

accepted definition of alcoholism is that it is a disorder characterized
by excessive drinking that results in injury to a person's health or adequate social functioning or both (Mendelson, 1970).

A number of inves-

tigators have employed specific pharmacologic criteria of addiction for
selection and description of their research subjects.

These pharmacol-

ogic criteria for alcohol addiction are the same as those employed for
a variety of other addictive disorders--tolerance and physical dependence.
Tolerance is demonstrated when, after repeated ingestion of a
drug, increasing dosage must be used to give effects obtained in the
original dose.

Although there is tolerance observed in alcoholics, there

is little evidence that altered EtOH metabolic processes can adequately
account for the degree of tolerance that occurs.

Cellular adaptation to

EtOH has been advanced as a more parsimonious hypothesis to explain the
phenomenon of tolerance (Mendelson, 1970).
Axelrod (1968) has reviewed data relevant to the several mechanisms that may underlie cellular adaptation in the development of tolerance to drugs.

Although the models he has described were based upon
1

2
the possible action of narcotic analgesics, they have relevance for other
centrally-acting drugs such as EtOH.

Three possible factors are discuss-

ed: (1) reduced activity of the drug receptor, (2) depletion of endogenous
substances that indirectly cause or mediate the drug action (transmitters),
(3) enhanced metabolism or inactivation of the drug.

There is much ev-

idence against the last of these factors with regard to EtOH.
Axelrod (1956), studying morphine tolerance, has suggested that
the first factor, drug-induced reduction of receptor-site activity, may
cause the development of tolerance to that drug.

These receptor sites

may be enzymes, since liver N-demethylases, morphine catabolic enzymes,
decrease in activity after continuous exposure to morphine.

He postulat-

ed that a similar phenomenon might occur in the brain since the molecular
structure of drug receptors in the central nervous system closely resemble the N-demethylating enzymes in the liver microsomes.

However, chal-

lengers to this theory have argued that development of tolerance to narcotics can occur in rats without reduction of N-demethylating activity
(Axelrod, 1956).

In summary, Axelrod stresses the fact that isolation

and characterization of analgesic receptors in the central nervous system
are necessary precursomto testing hypotheses concerning reduction of
receptor site activity by centrally acting analgesic drugs.
The tolerance to EtOH may be mediated by endogenous putative
transmitters, the second factor mentioned by Axelrod.

There is some

indirect evidence that this tolerance may be associated with a decreased
release of acetylcholine.

However, the findings of Gage (1965) indicate

that EtOH acts to increase rather than to decrease the rate of transmitter
release.

This is consistent with neurophysiologic findings that alcohol

depressed spinal cord reflexes without affecting synaptic transmitters.

3

In line with these results are reports by Israel (1970) 1 that EtOH
suppresses active transport of ions in nervous tissue by inhibiting
Na+-K+-Mg++-- ATPases through competitive inhibition with potassium.
One of the major difficulties in exploring cellular adaptation in
laboratory animals has been the surprising lack of effect of EtOH on a
number of measurable indices when EtOH is administered in relatively
physiologic concentrations.

Suppression of several types of neurochemical

and neurophysiologic activities has been reported with extraordinarily
large doses of alcohol in in vitro systems.

However, it has been dif-

ficult to ascertain an appreciable inhibition of cellular function when
concentrations of EtOH are employed that produce inebriation rather than
death (Israel, 1970).
Goldstein and Goldstein (1968) have developed an enzyme repression theory of drug tolerance and physical dependence.

This theory,

which conceives of tolerance and physical dependence as a unitary mechanism, is based on the processes of repression and derepression of enzyme
synthesis.

In terms of an excitatory neuro-compound, for example NE, it

is known that the synthesis of the

~E

synthetic enzymes (NSE) is decreas-

ed by increased levels of NE, i.e. end-product repression.

These authors

postulate that inhibition of NSE activity by a drug such as EtOH would
produce an immediate effect by decreasing the concentration of NE.

This,

in turn, would produce a depression of the NE excitatory function. Simultaneously, a decrease in end-product repression of NSE would result,
i.e. derepression.

As the concentratioIJSof enzyme NSE increased, more

NE would be synthesized.

In order to produce continued inhibition of

NSE, more drug (EtOH) would be needed.
of tolerance.

This could explain ·the phenomenon

Interestingly, chronic EtOH was seen to depress tyrosine

4

hydroxylase activity in rats, leading to depressed NE levels (Friedhoff,
1972).
In terms of physical dependence, it is thought that abrupt withdrawal of a drug EtOH would result in a very large concentration of
active enzyme NSE.

This large conce.ntration of enzyme, in turn, would

effect an enhanced synthesis of excitatory NE, and this great overproduction would have marked excitatory action (withdrawal symptoms).

Thus,

physical dependence results (Goldstein and Goldstein, 1968).
Of course, the origin of the alcohol withdrawal syndrome is quite
unclear, as are the critical determinants of the onset of withdrawal
symptoms, since either a relative decrease in blood EtOH levels or an
abrupt alcohol abstinence may precipitate this syndrome.

Abstinence

signs have been observed in subjects with blood alcohol levels as high
as 100 mg/100 ml (Isbell et al, 1955).

Withdrawal onset does not appear

to be related to dosage or duration, since Mello and Mendelson (1970)
have also observed partial withdrawal signs of tremors in subjects who
have been drinking small amounts of alcohol for as little as four days.
In chronically intoxicated alcoholic humans, many of whom have other
associated pathologies, withdrawal symptoms can involve tremor, hallucinations, and grand mal seizures, with a peak incidence 24 hours after the
cessation of drinking.

The syndrome of delirium tremors (D.T. 's), a

state characterized by gross tremor and agitation, disorders of sense
perception, and increased psychomotor and autonomic nervous system activity, has its onset between 72 and 96 hours following the cessation of
drinking (Victor and Wolfe, 1973).

Thus, two "subsyndromes" may follow

EtOH withdrawal.
EtOH toxicity and withdrawal symptoms may be due to (1) direct

---
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actions of EtOH; (2) psychoendocrine factors, e.g. increased CA secretion
and enhanced release of adrenocorticotrophic hormones can be induced by
EtOH; or (3) through neurophysiologic "denervation supersensitivity,"
wherein EtOH may be causing a depression which is followed by a rebound
super-excitation upon removal of the EtOH.

This latter concept was

noted by Jaffe and Sharpless (1968), since many withdrawal phenomena
involve an exaggeration of behavior that is ordinarily suppressed by the
agent that induces dependence.

Finally, (4) EtOH may cause the formation

of some new products, possibly alkaloids, that may play a part in the
neurological aspects of withdrawal syndrome and physical dependence.

6

II.

ETHANOL:METABOLISM
"The sway of alcohol over mankind, 11 according to William James,

"is unquestionably due to its power to stimulate the mystical facilities
of human nature 11 (James, 1902).

But mystical sway has been variously

interpreted as having psychological, social, cOr biochemical bases, or
combinations of these.

The last, biochemical factors in alcoholism, has

created intense interest in biomedical science of late.

The study of

alcohol and its related pathologies is vital to the betterment of over
nine million Americans who have been classified as alcoholics.

The origin

of their affliction may be psychological or physical, if such a distinction can be made, and as such these heterogeneous persons are now labelled as psychologically dependent and/or physically dependent, rather than
by the older term of "addicted " (Mendelson, 1970).
While it is generally recognized that ethyl alcohol is the chief
intoxicant that innnediately affects one after he drinks commercial liquor,
there are probably other chemicals involved.

Chemicals used for coloring

and taste purposes, called congeners, are known to have toxicities of
their own, for example, in bourbon.

Hangovers in the "morning after"

have been suggested as stennning from alcohol-induced brain meningeal edema,
or possibly from toxic glycol products of catecholamines (CAs) created by
a metab9lic shift caused by EtOH (Smith and Gitlow, 1967). Others believe
that increased diuresis, from suppression by EtOH of anti.diuretic hormone,
is responsible for some of alcohol's effects.

More specific evidence

has recently pointed at acetaldehyde (AcD), the proximal metabolite of
ethanol, as being at the root of some temporally later effects of EtOH
as well as of some neurological aspects.
The importance of AcD in the actions of EtOH as well as being

7

a factor in the etiology of alcoholism has been minimized in the past
largely because of the relatively small amounts produced in the normal
metabolism of alcohol.

This appraisal has been based largely upon a

limited amount of blood level data obtained by chemical methods which
have been criticized recently for lack of specificity and sensitivity
(Truitt and Duritz, 1967).

Furthermore, AcD has been recognized as being

directly responsible for a large number of actions in the acute and
chronic intoxication syndromes produced by alcohol.

AcD is a potent

hypnotic in its own right, or in its tricyclic form of sustained release
which is paraldehyde.
sweating.

In addition, it can induce nausea, vomiting, and

It causes release of CAs and depression of oxidative phos-

phorylation in isolated brain tissue.

Because the pharmacologic effects

of AcD are generally subjectively unpleasant, it has been suggested that
"while EtOH actions may be the reason that people drink alcohol, the
actions of AcD may be more related to why they stop." (Truitt and Duritz,
1967).

8

EtOH can be regarded as a drug as well as an oxidizable substrate.
It acts as a general depressant, despite thebelavioial stimulation that is
reflected in giddiness and increased activity.

This pseudo-stimulation

is most probably due to depression of inhibitory pathways in the brain.
There seems to be fairly good agreement that most of the effects of EtOH
as a depressant are not due to its metabolites but rather to the cellular
effects of the alcohol molecule itself (Israel, 1970).
As a group, general depressants have a high oil/water partition
coefficient, and the relative potencies of depressants have a good
correlation to their lipid solubility.

This concept is correlated with

the higher permeability of the blood-brain barrier for uncharged, lipophilic molecules.

Pauling showed that the general depressants share the

property of forming hydrated micro-crystals of the clathrate type
(Pauling, 1961).

These crystals would be formed by the depressant

surrounded by water and the charged side group of proteins, and could
conceivably prevent the catalytic activity of enzymes and other processes
by increasing the rigidity of the molecule in the biological system.
EtOH, as a depressant, should not be considered as a specific molecule,
but rather should be classified in a larger group.

It is, therefore,

important to study the effects of other general depressants to determine
whether they produce effects similar to those of EtOH by virtue of their
depressant ability alone.
EtOH

is metabolized chiefly in the liver by alcohol dehydro-

genase (ADH) to form acetaldehyde (AcD).

It is generally accepted that

EtOH is not metabolized to any great extent in brain and that activity

9

of brain ADH is very low (Raskin and Sokoloff 1972).

Until the recent

interest in the microsomal ethanol-oxidizing system (MEOS), (Orme-Johnson
and Ziegler, 1965), it was believed that ADH was the major, if not the
exclusive, enzyme responsible for catalyzing 90-98% of the initial oxidation of EtOH to AcD in liver.

Hepatic ADH is a zinc-containing enzyme

found mainly in the soluble fraction of the liver cell.

It has a pH

optimum of 10.4 and is NADtdependent.
Recently, another hepatic enzyme system has been implicated as
having a potent, important role in the oxidation of EtOH to AcD and
methanol to formaldehyde.

In 1965, Orme-Johnson and Ziegler described a

hepatic MEOS that appeared similar to a variety of drug-metabolizing
enzymes found in the liver.

This microsomal oxidase system is dependent

on NADPH and has a pH optimum of 7.2.

Interestingly, chronic administra-

tion of EtOH to rats resulted in as much as a 200-fold increase in MEOS
activity but with no significant increase in ADH activity (Lieber and De
Carli, 1968).

These authors

also reported that pyrazole, an inhibitor

of ADH, did not block the induced increase in rate of blood EtOH clearance
seen in EtOH-treated animals.

As stated before, alcohol tolerance does

not appear to stem from increased ADH synthesis.

However,Von Wartburg

(1971) has described an atypical ADH in human liver.

Atypical ADH has a

different substrate specifities, different metal-binding characteristics,
and different pH activity curves compared to typical ADH isoenzymes.
However, the fall in plasma alcohol concentration in individuals with
atypical ADH is only slightly increased .after acute EtOH drinking.
The degree of importance of the MEOS, if it truly is a discrete
enzyme, in the metabolism of EtOH and for the development of metabolic
tolerance and cross-tolerance in alcoholics, remains to be determined.
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Khanna et al (1970) have recently reported that contamination of in vitro
systems by a "catalase-type " enzyme produced by cellular disruption, was
responsible for the oxidation of EtOH by hepatic microsomal preparations.
It is known that EtOH is a substrate for catalase, although methanol has
four times the affinity for the enzyme.

Most investigators still believe

that ADH is the major enzyme responsible for the initial degradation of
EtOH to AcD.
However, the old idea that the ADH activity was the slowest and
thus rate-limiting step in the degradation of EtOH has recently been
challenged by Goldstein (1969).

He points out that the Michaelis constant

(Km) for the interaction of EtOH with ADH is about 2 x l0- 2M.

However,

high blood alcohol concentration of 400 mg/100 ml. would be equivalent to
8 x l0- 2M., and moderate intoxication with blood EtOH levels of 100 mg/
100 ml. would yield values equivalent to 2 x 10-2M.

It is therefore

apparent that ADH is half-saturated at moderate blood levels.

Goldstein

suggests that the availability of hepatic NAD is a major factor in regulating the zero-order kinetics of EtOH oxidation (that is, metabolism
proceeding at a constant rate independent of the concentration of EtOH).
This hypothesis is consistent with a number of studies that have clearly
shown that in vivo metabolism of EtOH is associated with a significant
decrease in hepatic NAD/NADH ratios.
EtOH metabolism can be appreciably enhanced by administration of
fructose (Carpenter and Leete, 1967).

This knowledge has not been

applied extensively clinically, although it has been postulated that
intermediates of fructose metabolism affect the dissociation of the ADHNAD complex.
The second major step in the degradation of EtOH involves the
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conversion of AcD to acetate or acetyl coenzyme A.

This reaction is

catalyzed by ALDH and requires NAD as a cofactor (Racker, 1949).

An

NADPH-dependent aldehyde reductase, different from ADH, also exists in
liver and brain.

It can reduce AcD and aldehydes of biogenic amines.

Low concentrations of barbiturates can inhibit aldehyde reductase, both
in vivo and in vitro (Tabakoff and Erwin, 1970).
It is well-known that the rate of oxidation of AcD is very rapid
and exceeds the rate of oxidation of EtOH.

Despite the short half-life

of AcD, it has been shown that a number of unique effects of AcD cannot
be produced by EtOH alone.
coenzyme A activity (Ammon

For example, AcD has been shown to inhibit
~

al, 1969) and pyruvate-stimulated oxidative

phosphorylation in brain mitochondria (Truitt and Duritz, 1967).

AcD

appeared to compete with or bind to pyruvate in the later experiments.
AcD may also affect the biotransformation and metabolism of catechol
amines and biogenic amines by stimulating the release of NE from neural
storage depots (Truitt and Duritz, 1966) and shifting the catabolism of
NE and 5IIT from oxidative to reductive pathways (Walsh and Truitt, 1969).
The mechanisms of action of ALDH are complicated to analyze since
the enzyme seems to exist in multiple forms and in multiple areas of the
cell.

The enzyme was discovered by Racker (1949) in beef liver acetone

powder extract.

Dietrich (1966) found it to be highest in liver, and

existing in most manunalian tissues including the brain, which is highest
in ALDH in the caudate nucleus.

Both mitochondria and cytosol contain

the enzyme, with recent work pointing to the mitochondria as the more
important during in vivo AcD

(Marjanen~

1972) metabolism.

Several forms of ALDH seem to exist, Dietrich (1973) having found
· by gel columns and isoelectric focusing two forms in mitochondria and the
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following three forms in supernatant-- (1) phenobarbital-induced, (2) not
phenobarbital-induced, disulfiram-resistant, oxidizing p-carboxybenzaldehyde but not propionaldehyde, and (3) having glycolaldehyde as a
substrate.

The enzyme or enzymes require NAD, optimally perform at pH

9.6-10, denaturing irreversibly above pH 10, 'and oxidize benzaldehydes,
aliphatic aldehydes, succinic semialdehyde, and aldehydes of endogenous
amines (Erwin and Dietrich, 1966).

AcD was found by the same workers to

have two Km's, indicating either the existence of two enzymes or substrate activation, the latter mechanism having been reported by Duncan and
Tipton (1971) for the substrates AcD and propionaldehyde.

There may be

NADP-dependent ALDH in mitochondria and microsomes, according to recent
reports by Tottmar and Kiessling (1973).
AIDH assays are usually done on tissue from male animals, largely
I

because steroids, which vary greatly in levels in females, can inhibit or
stimulate the enzyme (Maxwell and Topper, 1961).

Progesterone, testos-

terone and others inhibit ALDH independent of aldehyde concentration,
while estrone, diethylstilbesterol and othe1S stimulate or inhibit the
enzyme depending on substrate concentration.
Induction of rat liver ALDH after injection of mice with phenobarbital for four days has been reported (Cohen and Redmond, 1971),
probably due to the induction of the supernatant fraction of the enzyme.
These workers postulated that cross-tolerance between EtOH and barbiturates might exist if such an increase in AcD turnover occurred in animals
or man.
Several inhibitors of ALDH have been found, most of which have
little structural similarity to each other.

The pre-treatment of rabbits

with 2-chloroacetophenone blocks ALDH in brain slices, as evidenced by

13
decreased formation of acids from labelled NE (Rutledge and Dietrich,
1971).

Sulfhydryl groups within the enzyme appear to be crucial, since

administration of glutathione or various sulfhydryl reagents blocks the
inhibition.

A compound that inhibits ADH effectively, pyrazole, was

found to have no effect on ALDH activity in tat liver or brain (Dietrich
et al, 1971).

However, aldehyde reductase was inhibited by pyrazole in

the liver (but not in brain), the half-life of inhibition being 76 hours.
Both disulfiram (tetraethylthiuramdisulfide, Antabuse) and its
monomer, diethyldithiocarbamate (DDC), irreversibly decrease liver ALDH
activity after their injection into the live animal (Dietrich and Erwin,
1971).

This inhibition seems to involve sulfhydryl groups of the enzyme.

The return of activity appears to be dependent on protein synthesis,
being blockable by cycloheximide.
The severity of and unexplained human deaths from the disulfiramEtOH reaction ha\Bprompted a search for other drugs with a disulfiram(DS) like action that is sufficiently powerful to discourage drinking
but does not endanger life.

Ferguson (1956) has suggested citrated

calcium carbimide, also called Temposil, as another drug in the treatment
of alcoholism.

Its effects and mode of action seem to be similar to

those of DS, but its time relations are different.

A sensitizing action

to alcohol (flushing, palpitations, sweating, hypotension) is apparent
within 30 minutes (instead of 5-10 minutes with DS), and it lasts for
about 8-12 hours (rather than one-half to several hours after DS).
However, it has been argued that lowered dosage of DS is all that is
needed in most cases to remove the severe effects that are intolerable
to or life-threatening for certain individuals (Fox, 1973).
The hypoglycemic sulfonylureas may produce a reaction similar to
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the DS-EtOH reaction and cause the AcD concentration of the blood to rise
(Truitt and Duritz, 1972).
At least two pharmacologically important compounds are kno\vn to
inhibit both ALDH and ADH: the sedative chloral hydrate and the betaadrenergic blocker, propranolol.

Chloral hydrate is reduced to trichlor-

ethanol, a substrate and competitive inhibitor of ADH and thus a potentiator of EtOH intoxication, as in "Mickey Finn" knockout drops (Cooper
and Friedman, 1958).

The mechanism of ALDH inhibition by chloral

hydrate remains to be elucidated.
Propranolol is the widely used beta-blocker whose structure is 1(Isopropylamino) -3-(1-naphthyloxy)-2-propanol.

According to Duncan(l973),

the drug has been shown to inhibit several enzymes, including cholinesterase, monoamine oxidase, and the ca-H--induced activation of adenylate
cyclase while it is able to increase the activity of tyrosine hydroxylase
in rat striate cortex.

Duncan (1973) has recently shown that the inhib-

ition of ADH by propranolol is competitive with respect to NAD+ but mixed
with respect to EtOH, despite the hydroxyl group possessed by propranolol.
Propranolol inhibition of pig brain ALDH is reversible and of the mixed
type with respect to both NAD+ and aldehyde (3-methoxy-4-hydroxy-phenylacetaldehyde).
The kinetics of ALDH in pig brain have been described by Duncan
and Tipton (1971).

The enzyme binds its substrate and releases its prod-

ucts in a compulsory order: NAD+ is bound first, followed by aldehyde,
and NADH is released after the acid product.
ble and is not inhibited by the acid products.
tions are inhibitory.

The reaction is irreversiHigh aldehyde concentra-

Substrate activation by AcD or propionaldehyde, as

seen with other manunalian ALDH enzymes (Erwin and Dietrich, 1966), was
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seen by the authors, who postulated the existence of sub-unit inter-action or of different enzymes with different Km and V values.
In the present studies of ALDH, several compounds structurally
similar to PG were tested for in vitro inhibition of ALDH. Of the various
pyrogallol-related drugs tested for inhibitioµ of ALDH, only a limited
arr~unt

is known about the various actions and uses of these compounds.
Pyrogallol inhibits catechol 0-methyl transferase (COMT), dehydro-

shikmate reductase, D-amino acid oxidase, and histidone decarboxylase
(Webb, 1966).

It can be prepared from gallic acid, and its antioxidant

properties make it useful as a photographic developer and as an external
antimicrobial and skin irritant (Merck).

Propyl gallate is a very popular

antioxidant for foods, fats, and oils (Merck).

Hydroquinone is also a

useful antioxidant and photographic developer (Merck).

It is used occa-

sionally as a depigmentation agent in the treatment of hypermelanosis.
This latter action may be due to inhibition of tyrosinase (Merck). D-amino
acid oxidase is also inhibited by hydroquinone (Webb, 1966).

The two

methoxylated compounds, 3-methoxycatechol and 2,3-dimethoxyphenol, are
I

the products of 0-methylation of pyrogallol by COMT in vitro (Archer et al,
1960).

Shikimic acid (3,4,5-trihydroxy-cyclohexenoic acid), a non-aromatic

compound with three vicinal hydroxyl groups, is an inhibitor of plan dehydroshikmate reductase (Webb).
in aromatic biosynthesis (Merck).

In plants, it is an important precursor
RO 4-4602,an inhibitor of DOPA decar-

boxylase, has been used for the latter purpose to enhance L-DOPA levels
in patients treated for Parkinsonism.

Having the structure N - (DL-seryl)-

N2 -(2,3,4-trihydroxybenzyl) hydrazide, RO 4-4602 is basically a derivative of pyrogallol and seems to possess some of the same actions. Finally,
1,2,4-trihydroxybenzene, 3,4-dihydroxy-tolvene, and tetrahydroxyquinone,
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all have two or more hydroxyl groups on a benzene nucleus, and are thus
structurally related to pyrogallol.
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III.

ETHANOL:NEUROCHEMISTRY
More scientific light has been shed recently on the interrelation

of alcohol, aldehydes, and biogenic amines.

.In yjtro work by Majchrowicz

(1972) points to enzyme inhibition by AcD as being the major factor in
the effects of EtOH on amine metabolism.

He"found that (1) the reductive

shift was not necessarily caused by an increased NADH/NAD ratio, since
addition of NAD did not affect the increase in formation of indole glycols;
(2) monoamine oxidase (MAO) and catechol 0-methyltransferase (COMT) activity and NE uptake into synaptic vesicles are unaffected by EtOH 200 mM or
AcD 25 mM, and finally (3) ALDH is inhibited by EtOH-derived AcD, and its
decrease corresponds to decreased oxidation products of indolecholamines.

In support of point 3, the

and cate-

aldehyde-amine metabolism data,

is the work of Collins and Dietrich (1970).

When EtOH, 100-400 mg/100 ml,

was added to mouse tissue in vitro, a pyrazole-reversible 60% inhibition
of liver ALDH was seen.

The pyrazole effect suggests that AcD is res-

ponsible for the ALDH inhibition.

Another newly-discovered enzyme, al-

dehyde reductase, which reconverts AcD to EtOH and is important in brain
tissue, was increased 41% in mouse brain tissue following thirty days of
EtOH-metrecal drinking.
EtOH administration has produced contradictory results on neuroamine levels and on amine-biosynthetic enzyme activity as well as on protein synthesis in general.

Acute EtOH administration

d~'ressed

brain

protein synthesis in one study, while increasing synthesis when given for
ten days (Von Korff, 1970 ).

Tewari and Noble (1971),saw the reverse:

decreased synthesis of brain protein and RNA following chronic ingestion
of 10% EtOH.
tion in rats.

NE synthesis is also variably affected by EtOH administraHoping that an increased NE synthesis would be seen in
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order to explain alcohol tolerance, the opposite was seen by Friedhoff
(1972).

The activity of tyrosine hydroxylase, supposedly the rate-lim-

iting enzyme that converts tyrosine to dihydroxyphenylalanine (DOPA) en
route to NE, was depressed in caudate nucleus after repeated alcohol
injection.

Acute administration caused no change, stated Friedhoff.

EtOH is also known to be an.inhibitor of ion transport in nervous
tissue (Israel, 1972), probably contributing to its role as an inhibitor
of NE reuptake.

EtOH at 0.1-0.25% depresses Na 23 efflux (active trans-

port) without changing the action potential in rat brain cortex slices.
However, both active transport and action potentials were inhibited in
squid giant axons, although the active transport was more affected.
EtOH appears to compete with potassium

(IC'-) for a site on the Na+-K+-AT-

Pase enzyme; thus, the K+ concentration should be known in all experiments
involving EtOH and ATPase.

In the absence of added

IC'-, the concentration

of EtOH necessary to inhibit the ATPase by 50% is of the order of 0.20.3%.

This inhibition could be partly counteracted by increasing the

concentration of

IC'- in the medium.

EtOH (1%) significantly (25%) inhib-

ited the active accumulation of radioactive NE by rat brain slices incubated with 6 mM K+.

EtOH (1%), however, did not affect the passive efflux

of NE from preloaded brain slices nor its release when elicited by
electrical stimulation, thus indicating that the action potentials are
not inhibited.
The theory of EtOH as a homeostatic regulator of amine levels
has been advanced by Bacopoulous and

co~orkers

(1972).

They have found

an existing correlation between alcohol preference and brain neurotransmitter level changes in CFl mice.

Animals that "pursued" 2% alcohol

solution in preference to water, had neuroamine levels resembling mice
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that had been stressed by electroshock.

Thus, increased 5HT and decreased

NE levels were seen in stressed mice and in EtOH pursuers.
served to restore these "stress" levels to that of controls.

EtOH apparently
That is,

"the reinforcing properties of alcohol are attributed to its intrinsic
stabilization of the labile neurotransmitter levels."

As such, one may

partly explain "addictive personalities" of animals and possibly humans
in terms of inherited amine stability.
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IV.

CATECHOLAMINES=BIOSYNTHESIS AND METABOLISM
The CAs, NE, E, and DA, are 3,4-dihydroxyl derivatives of phenyl-

ethylamine.

They are widely distributed throughout the animal kingdom,

most often in nerve cells.

CAs are found in the peripheral sympathetic

nervous system and in the adrenal medulla, and are unequally distributed
in different areas of the central nervous system (CNS).

Small amounts

of CAs are also found in chromaffin cells scattered throughout the body.
The subject of their pharmacology and biochemistry has ben reviewed by
various authors (Axelrod,1971; Kopin,1969; Molinoff and Axelrod, 1971).
NE is highly localized in peripheral postganglionic sympathetic
nerves.

Its concentration in some sympathetic ganglia maybe as high as

100 microgram/gm, while in sympathetically innervated tissue its concentration ranges from 0.1 to 0.2 microgram/gm.

The nerve endings make up

only a small pa.rt of the total mass of the tissue, and thus the actual
concentration of NE in the endings is probably between 100 and 500 microgram/ gm.
of

Postga.nglionic stimulation leads to almost complete disappearance

NE from tissues, which suggests that it is wholly contained within

the sympathetic nerves.

In the CNS, the highest concentration of NE is

found in the hypothalamus and brain stem.

(Axelrod, 1971)

NE is released from sympathetic nerve terminals as a neurotransmitter and exerts most of its effect locally on post-synaptic cells.
Epinephrine (E) functions mainly as a hormone, being released into the
general circulation primarily from the adrenal medulla.
E have been found in mannnalian brain and heart.

Small amounts of

A third CA, DA, serves

as a precursor of NE and E in both the peripheral and central nervous
systems.

Its most important function may be in the brain, where high

concentrations are found in the striatum.

DA is thought to be a synaptic
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transmitter functioning to mediate inhibition in a motor-coordinating nigro-striatal pathway.

Deficiency of DA in this area appears to be a . bio-

chemical correlate of Parkinson's disease.
It has recently been possible to visualize CAs .in

~.

A high-

ly specific and sensitive fluorescent histochemical method has permitted
the direct visualization at a cellular level of the biogenic amines DA,
NE, E, and 5HT.

The'use of this technique has confirmed the conclusion

that the NE present in peripheral mammalian tissue is localized almost
exclusively in sympathetic nerves.

More specifically, the use of gradient·

centrifugation techniques, the autoradiographic localization of tritiumlabelled NE, and electron microscopy have combined to show that NE is
localized not only within the sympathetic nerve endings, but also largely
within specific vesicles contained in these nerve endings.(Axelrod, 1971)
CAs influence the actions of a wide variety of tissues such as
vascular smooth muscle, adipose tissue, liver, heart, and brain.

In many

cases they act by causing an increase in the activity of a specific enzyme or enzymes.

These effects are frequently mediated by adenosine 3 1

,

5'- monophosphate (cyclic AMP).
The biosynthesis of CAs begins with tyrosine.
involved _in CA

~iosynthesis

-- tyrosine hydroxylase

The four enzymes
(TH), DOPA decar-

boxylase (DOPA-D}:lopamine B-hydroxylase (DBH), and phenylethanolamine Nmethyltransferase (PNMT) -- do not have the same subcellular distribution.
Thus, intracellular migration of substrates for these enzymes takes place
as tyrosine is converted to NE in the sympathetic nerves and to E in the
adrenal medulla.
Although the pathway of tyrosine to DOPA to DA to NE to E is the
major pathway of CA biosynthesis, lack of specificity of several enzymes
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involved permits several alternate pathways.

One such pathway from

tyrosine to NE and E may exist via tyrosine, tyramine, octopamine and
synephrine.
NE.

There is also a pathway from tyrosine to E which bypasses

In this reaction sequence, DA is converted to epinine by a non-

specific phenyalkalamine N-methyltransferase which has been found in
rabbit lung.

Epinine can then be beta-hydroxylated by DBH to form E.

Although CAs are rapidly inactivated when they enter the bloodstream, they are stored in high concentration in the adrenal medulla,
sympathetic neurons, and certain areas of the brain.

In the adrenal

medulla they are held in granules that contain high concentrations of ATP
in a CA/ATP ratio of 4:1; DBH; a group of nine specific proteins called
chromggranins, having a molecular weight of about 77,000; and an ATPase
dependent on Mg+t and Ca+t.

These granules can take up radioactive E

from solution by an energy-dependent process inhibited by drugs such as
reserpine.

On the basis of these observations, it is believed that the

CAs in the granules are bound in a protein-ATP complex that may involve
a divalent anion.
In the sympathetic nerve endings, NE is similarly found in the
particulate fraction that contains dense-core vesicles.

Only those

amines that are bound in vesicles are released by nerve stimulation; and
if binding in vesicles is prevented, even NE present in the soluble fraction is not released.

Drugs such as reserpine, which deplete NE, cause

disappearance of the dense-core vesicles.

NE and E appear to be stored

in two different granule types in the adrenal medulla.
The chemical structures relevant to binding have also been
studied.
group.

NE has a catechol group, a beta-hydroxyl group, and an amine
To determine which chemical structures may be involved in the
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binding mechanism, related compounds that lack one or more of these
groups have been studied.

The amine group is necessary for binding.

Phenylethylamine, which has only the amine group but none of the hydroxyl
groups, is not bound; but phenylethanolamine can be bound by the vesicles
to a slight extent.

The beta-hydroxyl group, therefore, appears to con-

tribute to binding.

DA, which lacks only the beta-hydroxyl group of NE,

is relatively strongly bound to the vesicles; thus, the catechol group
appears to be involved in the binding mechanism.

When either of the

catechol hydroxyl groups of NE is lacking, as in m-octopamine or p-octopamine, the avidity for binding sites appears to be diminished in vivo
as well as in vitro. This incomplete specificity of binding allows replacement of NE by other amines, so-called "false transmitters."

Accu-

mulation of false transmitters in vesicles diminishes the amount of NE
that is released, thereby causing a partial adrenergic blockade when less
active NE reaches the receptor site. (Molinoff and Axelrod, 1971).
Endogenous amines apparently are released by nerve stimulation
only if they are bo4nd in vesicles.
compound from
be present.

nerv~

However, mechanisms for releasing a

endings that do not involve vesicle binding may also

Bretylium is a quaternary amine that interferes with the

release of NE from the sympathetic nerves.
bretyli:um

Although not bound in vesicles,

accumulates in sympathetic nervous tissue and is released

during nerve stimulation.

It is thus apparent that a substance need not

be bound in vesicles in order to be released.
NE that is released at the adren:ergi.c nerve ending reaches an
effector cell where it reacts with a specific site, the receptor, to
initiate a sequence of evehts that leads to a response.

Adrenergic re-

ceptors have been separated into two main types, alpha and beta, based
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on the structure-activity relation of various compounds (agonists) that
intereact with the receptor.

The order of potency at the alpha receptor

(e.g. vasoconstriction) is NE

>

E

>

isoproterenol.

At beta receptors

(e.g. vasodilatation or myocardial chronotropicity) this order is reversed (Kopin, 1969).
Further, the notion that there are two main types has been greatly strengthened by the discovery of drugs that specifically block one but
not the other type of receptor (Kopin, 1969).
In addition to responses that involve muscular contraction or
glandular secretion, CAs have several metabolic effects (e.g. hyperglycemia).

The mechanism of a number of these effects has been shown to be

increased formation of cyclic AMP from ATP as a consequence of activation
of adenyl cyclase.

There is some evidence that the beta receptor is

pharmacologically similar to the site of interaction that results in
activation of adenyl cyclase (Kopin, 1969).
After release, rapid inactivation of CAs occurs, primarily (80%)
due to uptake into the presynaptic nerve endings.

The neuronal uptake

mechanism obeys saturation kinetics of the Michaelis-Menten type, requires energy derived from glycolysis or oxidation, is stereospecific
for the L-isomer of NE, and requires the sodium ion.

Many other amines

can be taken up and stored in sympathetic nerves by a neuronal uptake
process.
and DA.

These amines include tyramine, alpha-methyl NE, metaraminol, E,
Cocaine and antidepressant drugs such as imipramine and sympa-

thomimetic amines (amphetamines) block the uptake of NE in the nerve.
Compounds that block uptake also prevent the inactivation of NE and thus
prolong its physiologic actions (Molinoff and Axelrod, 1971) .

•

An extraneuronal uptake process for NE, called uptake 2, has been
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found which is blocked by normetanephrine (a metabolite of NE) and by
adrenergic blocking agents like phenoxybeuzamine.

Uptake 2 operates at

all concentrations of CAs to transport the amines into nonneuronal tissues
where they are subsequently metabolized.

Compounds such as E and iso-

proterenol which have a relatively low affinity for intraneuronal uptake
and a high affinity for Uptake 2 may be inactivated mainly by the latter
process (Axelrod, 1971).
According to Molino££ and Axelrod (1971), the main CA catabolic
enzymes are catechol 0-methyl-transferase (COMT) and monoamine oxidase
~1AO).

These enzymes act on CAs to produce physiologically inactive

metabolic products, but neither of these enzymes plays an enormous role
in terminating the physiological action of the neurotransmitter NE or of
the hormone E.

The rapid inactivation of CAs is due to reuptake into

presynaptic endings.

It has been estimated that 80% of NE released in

sympathetic nerve endings is inactivated by reuptake, with 20% being
catabolized by enzymes.

COMT appears to be more important than MAO in

metabolizing E and NE in the rat.

In addition to these two major enzymes

of CA metabolism, two other enzymes -- aldehyde dehydrogenase and aldehyde reductase -- are present and act on the products of MAO and COMT
actions.

In humans, vanillylmandelic acid (VMA), the product of COMT,

MAO and aldehyde dehydrogenase action on NE and E, makes up about 40% of
the total urinary CA metabolites.

The primary metabolite of NE from

brain is 3-methoxy-4-hydroxy-phenylglycol, formed via COMT, MAO, and
aldehyde reductase. About one-third of the total CA metabolites in human
urine comes from DA (Molinoff and Axelrod, 1971).
f
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The search for CA 0-methylating enzyme was prompted by the
observation that NE and E are metabolized to the corresponding 3-0methylamines, normetanephrine and metanephrine, respectively.

COMT,

first described in rat liver, requires S-adenosylmethionine (SAM) as a
methyl donor.
and ATP.

SAM is synthesized throughout the body from methionine

COMT requires divalent cations

such as Mg-++ for activity,

but other ions can substitute, including manganese, cobalt, zinc, iron,
cadmium, and nickel.
Rock et al (1970) compared the properties of rat brain COMT
with that of liver.

The two enzymes have similar pH optima, heat stabil-

ities, molecular weights, and responses to inhibitors.

However, brain

COMT was found to have one less activity band (by electrophoresis) and
one-tenth the specific activity of the liver enzyme.

The optimum activ-

ity of COMT from either organ was obtained at pH8, using 0.01 M Mg-++.
The substrates for COMT include NE, E, DA, DOPA, 3, 4-dihydroxymandelic acid, 3, 4-dihydroxyphenylacetic acid, 3-hydroxyestradiol, and
ascorbic acid.

The latter can be 0-methylated on the alpha-carbon after

forming a cyclic ether.

The enzyme can also 0-methylate exogenously

.

administered catechols such as 3,4-dihydroxyephedrine, 3,4-dihydroxyamphetamine, and a variety of substituted catechols and polyphenols but
not monophenols (Axelrod, 1968).
In vivo, 0-methylation occurs mainly on the meta position. Polyphenols with non-polar side-chains such as acetophenones, however, may

27
have up to 50% para 0-methylation.

A novel type of interconversion of

4-methoxy-3-hydroxy-acetophenone to 3-methoxy-4-hydroxy-acetophenone
occurs in vivo.

This results from the 0-demethylation of the 4-methoxyl

compound to form a catechol which is subsequently 0-methylated on the
3-position by COMT,
that

according

to

Creveling

~al

(1970), finding

COMT has a molecular weight of approximately 24,000.

At least

two separate forms have been identified on starch-block electrophoresis.
The enzyme can be inhibited by dichloromercuribenzoate, which
suggests that the enzyme has a sulfhydryl group in the region of its active site.

Chelating agents such as tropolone can inhibit COMT.

A

normally occurring catechol compound that blocks 0-methylation in vitro
and in vivo is 3-hydroxyestradiol.

Other competitive inhibitors are

dihydroxyphenylacetamide, pyridoxal phosphate, and polyphenols such as
pyrogallol

(l,2,3~trihydroxybenzene).

Another group of COMT inhibitors

are substituted 3,5-dihydroxy-4-methoxybenzoic acids, which act noncompetitively and are effective in vivo.

~al,

(Nikodejevic

1970)

The inhibition of COMT by pyrogallol (PG) is of interest because
of the bearing it has on the metabolism of E and NE.

Bacq (1936) observ-

ed that PG increased the responses of tissues to sympathetic nerve stimulation and to E.

However, he then attributed this action to the anti-

oxidant properties of PG.

The inhibition of COMT was reported by Bacq

who believed that this could explain the sensitivity of smooth muscle to
the CAs by PG and other phenolic compounds.

The half-life of NE in mice

is increased from 22 to 42 minutes by 10 mg PG,

(Webb,~

1966), while

0-methylation is inhibited 99%, indicating other pathways for NE metabolism.

Probably the MAO pathway is also important.

The administration

of PG to rats does not by itself increase brain NE levels, but it does
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in conjunction with iproniazid (MAO inhibitor),since the two major NE
degradation pathways are blocked (Jaattela and Paasonen, 1961).
Repeated administration of PG causes a rise in blood pressure,
but this is soon followeiby a loss of response or tachyphylaxis.

The

rate of urinary excretion of 0-methylated derivatives of the CAs is
briefly decrease by PG, but if the administration is continued, the rate
returns to normal.

Long-term tr.eatment with PG leads to an increase in

COMT and MAO activity in the liver of rats, so it may well be that these
enzymes are adaptively altered.

Excretion of 0-methylated products of

CAs reach a minimum at five days, returning to normal in twenty-five
days.

Urinary CAs,on the other hand, increase for twenty days, then

slowly return to their pre-PG levels, despite continued PG injections
(Wylie et al, 1960)
The kinetics of in vivo inhibition of COMT have been studied by Crout
(1960). Inhibition occurs very rapidly in liver, heart and brain even
when the PG is injected i.p., and by 30 minutes has developed appreciably.
PG inhibition lasts 30-60 minutes with a single dose of 200 mg/kg, but
last for several hours after injections of 50 mg/kg every 30 minutes for
several hours before in vitro assay, measuring NE conversion to normetanephrine.

The inhibition by PG is only partly competitive (actually the

curves appear to indicate noncompetitive inhibition) despite the fact
that PG is a substrate for the enzyme (Archer, 1960).

The Ki of 0.008 mM

for PG indicates the high potency of the inhibition (Km for NE is 0.3 mM).
The only other animal enzymes reported to be inhibited by PG are D-amino
acid oxidase, dehydroshikimate reductase, and histidine decarboxylase
(Webb, 1966).
COMT is localized in highest concentrations in the liver and

,,.......-
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kidney in most animals.

There is an unequal distribution of COMT in the

brain, activity being highest in the area postrema and lowest in the
cerebral cortex.

Although most of the enzyme is found in the soluble

fraction of the mammalian cell, there are also small amounts present in
fat-cell membranes, erythrocyte membranes, ahd in microsomes.

In sym-

pathetic tissue, COMT is present mainly outside the neuron, in contrast
to MAO which is present intraneutonally.
Recently the so-called peripheral beta-adrenergic receptor has
been suggested to be a membrane catechol-binding protein which may be
related to COMI' (Cuatrecasas et al, 1974).

Some well-known COMT inhib-

itors (tropolone, pyrogallol, and 3,4-dimethoxy-5-hydroxy-benzoic acid)
which do not have beta-adrenergic activity could inhibit the binding of
NE to liver microsomes, the.significance of which is controversial.
Physiologically, COM!' is involved in the metabolism of CAs
released into the circulation and in the inactivation of NE in tissues
lacking an abundant adrenergic innervation.

COMT may also be associated

with an extraneuronal uptake mechanism (Uptake 2).
Thus, the current concept of the adrenergic nerve has been
described.

The cell body manufactures vesicles and various synthetic

enzymes which are transported by axoplasmic flow to the nerve terminal.
Fast flow along the neurotubules carries the enzyme DBH, which converts
DA to NE.

The DA is derived from tyrosine which passes into the axon

and is acted upon by synthetic enzymes.

When stimulated by calcium, the

vesicle passes along a contractile neurofilament to fuse with the cell
membrane and' extrude the contents of the vesicle, including proteins,
DBH, ATP and NE.

After the "exocytosis," the vesicle reaggregates as a

smaller granule.

Release can be increased by reserpine, tyramine, and
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amphetamine.

The released NE can enter into any of four processes: (1)

NE can activate the receptor on the effector organ, this activation
being diminished when structurally similar "false transmitters" replace
some of the NE in the vesicles; (2) NE can pass into the circulation,
where other tissues will probably inactivate it; (3) NE can be taken up
by the neuron (Uptake 1) into presynaptic vesicles, and may be oxidized
by MAO before vesiculization, thus having to pass out of the cell into
the circulation; (4) NE can be taken up by other cells (Uptake 2), where
COMT and possibly MAO catabolize NE, the products of which will then be
excreted, probably as a glucuronide conjugation product of the liver.
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V.

ETHANOL AND AMINE-DERIVED ALKALOIDS
Scientific interest in aldehyde-plus-amine-derived isoquinolines

in alcoholism was stimulated in the 1960's by a fluorescence method for
the visualization of CAs in tissues which is based on formation of isoquinolines.

When freeze-dried tissue slices' are exposed to moist formal-

dehyde vapor at 80°c., the aldehyde and the endogenous CAs undergo a
Pictet-Spengler (1911) type of condensation via a Schiff base (imine)
intermediate to yield TIQ alkaloids.

Subsequently, these alkaloids are

oxidized to 3 ,4-dihydrois'oquinolines which tautomerize to fluorescent
quinone imines (Corrodi and Hillarp, 1964).
Collins and Cohen (1968),Robbins (1968), and others recognized
the structural similarities between these products and plant isoquinoline
alkaloids.

Robbins stated the

po~sibility

that trace amounts of TIQs

may form from AcD in vivo and have a relationship to alcohol addiction.
He also added that "pharmacologically significant formation of these
alkaloids might occur enzymatically, intracellularly or at sites of
localized, high concentrations of the reactants."

Possibly, they would

act as sympathomimetics during alcohol withdrawal, creating a need for a
depressant such as alcohol to restore physiological normalcy.

Collins

and Cohen reported the preliminary results of bovine adrenal perfusions
with AcD, in which simple TIQs derived from NE and E were detected.
Following this, several reports emerged of CA-derived TIQ formation in animals.

In vitro, TIQs were formed in cow adrenals after

perfusion with AcD. (100 fg/ml) also
fusion (Cohen, 1971).

cr~ated

TIQs through adrenal per-

Similar results in vivo were seen in rat adrenals

after intraperitoneal injections of methanol, using detection by fluorescence microscopy (Cohen and Barrett, 1969), or by thin-layer chromate-
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graphy (Collins and Cohen, 1970).
These studies were involved primarily with the CAs, norepinephrine
(NE) and epinephrine (E), while Davis and co-workers (1970) probed the
condensation reactions involving the CA, dopamine (DA), the inunediate NE
precursor localized chiefly in the caudate n~cleus of the marrnnalian brain.
Rather than examine only the AcD-DA condensation product, "salsolinol,"

Davis~

al studied the formation of a possible morphine pre-

cursor, tetrahydropapaveroline (THP), from the condensation of DA with
the aldehyde metabolite of DA.
in vivo
--

DA is known to be enzymatically oxidized

by monoamine oxidase to 3,4-dihydroxyphenylacetaldehyde
(DA-Ald).
.

---~

This unstable product is quickly oxidized by aldehyde dehydrogenase

(ALDH~

competitive inhibition of ALDH would occur, thus raising the

and a.

levels of DA-Ald.

This increased DA-Ald could then condense with the

parent amine, DA, creating the larger molecule THP.

EtOH-evoked diver-

sion of DA biotransformation to this benzyltetrahydroisoquinoline
alkaloid could be related to the dependence-producing properties of
alcohol, argued Davis.

That THP provides the starting point for the

elaboration of the complete morphine skeleton by the opium poppy has been
supported by tracer experiments (Leete, 1959).

The possibility was

suggested that animal systems could also mediate this specific reaction
sequence.

Davis makes the controversial case that many opium addicts

revert to alcohol and vice versa, because the biochemical mechanisms of
a~cohol

and opiate addiction are both opiate-based.

It is known, howev-

er, that rats susceptible to morphine addiction can also be addicted to
alcohol with greater ease than those which do not prefer morphine-containing water (Davis
Davis

et~.

1970).

et al (1970} did find that the formation of the alkaloid
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THP in rat brain homogenate occurred to a greater degree following the
addition of EtOH or AcD.

This effect was apparently due to inhibition of

ALDH, leading to decreased formation of 3,4-dihydroxyphenylacetic acid
from DA-Ald.

Further, the effect on THP formation of the cofactor nico-

tinamide adenine dinucleotide (NAD) was seen.

Enhanced THP formation was

seen, apparently as a result of greater acetaldehyde inhibition of the
oxidation of DA-Ald.

Another reason cited was the decreased formation of

salsolinol, due to rapid AcD oxidation, thus allowing a significant increase in the amount of DA available for reaction with its intermediate
aldehyde to form THP.
In the category of putative neurotransmitters in animals, the CAs
are joined by histamine, acetylcholine, serotonin (5-HT), and others.
is likely that many of these are affected by EtOH or AcD.

It

Interestingly,

the idea of AcD condensation products from 5HT-like amines has been advanced by Mclsaacs since 1961.

He reported the presence of a 1,2,3,4-

tetrahydro-beta-carboline alkaloid in the urine of rats treated with EtOH,
5-methoxytryptamine, iproniazid (a monoamine oxidase inhibitor), and
disulfiram (an ALDH inhibitor).

Various beta-carbolines can be synthe-

sized, e.g. from 5HT plus AcD, analogous to TIQ formation from CAs.
6-methoxy-1,2,3,4-tetrahydro-beta carboline is a brain serotonin elevator
in mice, possibly acting as an inhibitor of 5HT synthesis
1972).

(Mcisaacs~t

al,

Thus, isoquinolines and beta-carbolines may form after alcohol

ingestion.

They may act by altering neuroamine levels or by direct effect

upon receptor sites.
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VI.

METABOLISM AND PHARMACOLOGY OF BIOGENIC AMINE-DERIVED ALKALOIDS
The various alkaloid theories of alcoholism have been mentioned:

(1) CAs combining with simple alkaloids to form TIQs; (2) DA combining
with its aldehyde metabolite to create THP; and (3) serotonin derivatives
combining with simple aldehydes to yield beta-carbolines.

All of the

concepts revolve around the idea that plant-like alkaloids may form in
animals after alcohol ingestion.

The properties of these alkaloids pos-

sibly create some of the physiology of alcohol toxicity and withdrawal
symptoms.

Therefore, interest in isolating these compounds and their

metabolites in animal tissues has increased in recent years.
Metabolites of alkaloids in plants are reviewed in great detail
by Reti (1954).

0- and N-methylation are the principal processes involv-

ed in the interconversion of TIQ alkaloids, for example.

Many of the

products of these

reactions

are more toxic in certain ways than are

their precursors.

Demethylation also occurs, as in the conversion of

salsoline to salsolinol in desert cacti.
Many metabolic pathways followed by plant alkaloids are active in
animal tissue as well.

Numerous 0- and N-methylating enzymes, as pre-

viously described, methylate numerous endogenous amines. Catechol 0methyltransferase is widespread, inactivating CAs; guiacol 0-methyltransferase is reported to add a second methoxy group to 0-methylated DA products (Friedhoff et al, 1971); phenylethanolamine N-methyl-transferase
will N-methylate NE and other compounds (Axelrod, 1962); a nonspecific
N-methyltransferase in rabbit lung can act on 5HT, tryptamine, tyramine
and the CAs (Axelrod,1961); histamine N-methyltransferase, hydroxyindole
0-methyltransferase, demethylases, and water methylases also exist
(Axelrod 1962).
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Mixed-function liver oxidases are also known to form N-oxides of
hydrazines and of various arylamines such as morphine, nicotine, chlorpromazine, and amphetamine.

The nitroso products can be reconverted to

their precursor using cytochrome

reductase.

The regulatory site can

be activated by amphetamine or various phenylethylamines.

Modifiers of

the oxidases include barbiturates, which increase oxidative demethylase
activity, and amphetamines, activators of N-oxidase in human and pig
liver. N-oxides of heterocyclic compounds such as T!Qs are seen in plants
(Ziegler, 1972).
The mechanisms of actions of TIQ alkaloids in animals have been
investigated.

They easily foltn.in vitro in adrenal tissue, as stated.

Other areas where these alkaloids might form are in the adrenergic fibers
of the sympathetic nervous system and brain.

These alkaloids retain the

original CA structure, but ring closure prevents rotation of the ethanolamine side chain.

If the resultant conformational site were to corres-

pond to that required for binding to smooth muscle or brain receptor
sites, these substances could be unique neurotransmitter or blocking
agents.

They appear to be bound to adrenal, brain and nerve tissue,

possibly at the same loci as CAs.

Cohen and Collins (1970) suggested

that TIQs alkaloids, either actively secreted or leaked from nerve terminals, could contribute to the behavioral changes.caused by alcohol.

A

portion of the characteristic neurologic disturbances, such as hyperexcitability, tremulousness, hallucinosis, and seizures, which occur
when blood concentrations of alcohol are falling or absent, could be due
to the persistent physiologic action of the TIQ alkaloids.
The TIQ alkaloids derived from the CAs are structurally similar
to a number of naturally occurring alkaloids, such as anhalamine, salso-
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line, and carnegine, which are found in desert cacti, (Reti, 1954) and
which exhibit pharmacologic actions such as excitation, narcosis, blood
pressure changesand convulsions.
an

Five to ten milligrams of pellotine,

anhalamine derivative, can cause convulsions in a frog.

The most

toxic of this group, lophophorine, tetanizes a frog at levels of 250
micrograms.

But dose-dependent qualities exist, especially so at the

12.5 milligram level, above which blood pressure drops in intravenously
injected rabbits, while higher pressure occurs below 12.5 milligrams.
According to Schultes, (1969) the TIQ alkaloids found in peyote
are hallucinogenic and are responsible for the differences between the
intoxication state produced by peyote versus that produced by pure
mescaline, the major active ingredient.

The reported pharmacological

properties of TIQ derivatives of CAs include inhibition of uptake and
storage of CAs in nerve and brain.

Cohen (1973) demonstrated that 6,7-

dihydroxy-TIQ (DA-derived) is accumulated by rat iris, sympathetic nerve
endings, and brain synaptosomes.
uptake in brain synaptosomes.

This TIQ was shown to block NE and DA

Intraventricular injection of this TIQ

caused a dose-related decrease in the body temperature of rats, shown to
be related to the release of CAs.

Thus a DA-derived TIQ, as well as

other related alkaloids (Alpers et al, 1974), possess properties that
would serve to prolong or enhance the physiological effects of the CAs.
Biosynthesized TIQs may then function as false adrenergic transmitters.
Direct pharmacological effects of CA- related TIQs have been
shown.

The complex benzylisoquinoline derivative of DA, tetrahydro-

papaveroline (THP), is reported to act as a direct beta-sympathomimetic
agent (Santi et al, 1972).

The EEG stimulant effect of condensation

products of AcD with mescaline, spermidine, tryptamine,

gl~tamine,

and
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histidine, is greater for the condensation product than for the parent
amine (Beck et al, 1968).

Similarly, it has been seen that

- the

reversal of pentobarbital sedation occurs to a larger extent with the
TIQs than with NE (Goldstein, 1970).
Of possible significance is the report by Heath (1965) that
schizophrenics under aldehyde-elevating disulf iram therapy are noticed
to undergo a worsening of their mental condition.

This response might

in part be due to the stimulant effect of condensation products formed
from endogenous amines with the increased aldehydes.

Of course, other

toxic effects of disulfiram may be active in this case as well..

In a

survey of pharmacologic actions of synthetic, phenolic TIQs, all lacking
the 4-hydroxyl group of NE-derived TIQs, Hjort et al (1938) observed
effects on blood pressure, respiration, and smooth muscle, as well as
anti-anesthetic properties, blockade of pressor responses to epinephrine,
tremor, and convulsions.

Recently, L. Goldstein (1970) found a mescaline-

like reversal of pentobarbital sedation following injection of a 6,7dimethoxy-TIQ in rabbits.

The pharmacology of the 4-hydroxy..lfIQ alkaloids

used in the· experiments in this dissertation research has not yet been
studied.
A. Collins et.al (1973) recently reported the 0-methylation in
rat brain and liver

of both salsolinol, a DA-AcD condensation product,

and of THP, a DA-derived benzylisoquinoline.

Salsolinol was a better

substrate in vitro for COMT than was its parent amine, DA.

Salsolinol

also served as a moderate competitive inhibitor of both COMT and MAO,
although no specific metabolite of these alkakids was detected after
incubation with MAO.

It is not known whether MAO can break the hetero-

cyclic ring of the TIQs in order to achieve possible deamination.

THP
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was found by these workers to form two 0-methylated products, while
salsolinol yielded only one.

0-methylation in vivo and in vitro via COMT

also was reported for trimetoquinol (Meshi, 1970), another benzylisoquinoline related to THP.

Similarly, N-methylation has been reported for

harmaline, a compound that has a beta-carboline structure and MAO inhibitory activity (Ho et al, 1971).

However, the metabolism of beta-hydroxy-

TIQs, such as those derived from NE, has not been studied prior to this
work.
Thus, much of alkaloid metabolism in animals is similar to that
in plants.

And further, CA-derived TIQ alkaloids seem in the limited

studies done thus far, to be handled through the same metabolic pathways
as their parent CAs.
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VII. ANIMAL MODELS FOR ALCOHOLISM
Since the demonstration by Isbell et al (1955) that the alcohol
withdrawal syndrome can be induced in man under controlled laboratory
conditions, progress in the research of EtOH dependence has been slowed
by the lack of suitable animal models.

Richter (1956) has never observ-

ed overt alcohol intoxication with withdrawal symptoms in laboratory
rats.

He found intoxication in only three of thirty wild Norway rats

drinking aqueous EtOH solutions as the only liquid.

Rats have a tendency

to avoid such solutions entirely, or drink only at night, becoming sober
by sun-up.

More recently, convulsions and "hallucinatory behavior" were

induced in five dogs following withdrawal of alcohol administration
through surgically implanted gastric cannulae (Essig and Lam, 1968).
The evaluation of this animal model is difficult because the dogs developed gastrointestinal ulcerations and possible hypoglycemia, due to
absent or markedly diminished food intake during the withdrawal period.
Ellis and Pick (1971) have also developed an alcohol intubation
technique that can produce human-like withdrawal symptoms in monkeys and
dogs, after three and six weeks of EtOH ingestion, respectively.

The

mean daily dose of EtOH is increased from 2 g/kg to 5-6 g/kg, an amount
that is approximately equal to two pints of 100-proof distilled beverage
consumed daily by a human subject weighing 150 pounds.
generally fluctuates between 100 and 500 mg/100 ml.

The blood EtOH

Withdrawal symptoms

were classified into the following stages of progressive severity: (1)
tremulous, (2) spastic, and (3) convulsive.
stage 3 in untreated animals.

Death may or may not follow

Administration of EtOH or barbiturates in

these animals will entirely interrupt the withdrawal reactions at any
stage.
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For reasons of economy, however, most investigators prefer to
use smaller animals, specifically rodents, in their search for an animal
model for alcoholism.

In the past, the two reasons cited for the inabil-

ity to induce alcohol withdrawal reactions in laboratory rodents by the
forced drinking of aqueous EtOH solutions were: (1) The total amount of
EtOH which can be administered orally in aqueous solution is too small,
and (2) the EtOH is consumed predominately during the night, leaving the
daytime for recovery.

Preliminary experiments by Freund (1969) with

10-25% aqueous EtOH solutions as the only drinking fluid demonstrated
that mice consumed only up to 22% of calories in the form of EtOH and
drank only during the night.

Liquid diets of an EtOH-Metrecal mixture as

the sole food were lethal within two weeks in Freund's lab when 45% or
.more of calories were supplied in the form of EtOH.

Feeding of liquid

diets containing 35% of EtOH-derived calories resulted in nearly even
distribution of fluid intake between the day and night hours and were
well tolerated.

Freund has described an animal model that used initial

30% weight reduction of mice followed by forced choice presentation of
liquid diets containing EtOH 6% of volume, or 35% of total calories.
Apparently, weight reduction decreased the rate of EtOH degradation in
these animals.
Freund claims to have induced seizure disorders, and later learning deficits, after abrupt replacement of alcohol by isocaloric sucrose
in the basic liquid diet.

Withdrawal was begun after the mice had been

moderately to severely intoxicated in at least two-thirds of the daily
ratings for four to five days.

Light intoxication was defined as ataxic

but rapid gait; severe as coma with::>ut righting reflexes; and moderate
as in between light and severe.

After substituting isocaloric amounts of
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sucrose for EtOH, four stages of withdrawal were noted: (1) overactivity,
sq~ing,

generalized tremors 1-5 seconds in duration; (2) stage 1 plus

rapid tail-beating; forward arching of the tail over the back to the nose
(so-called Straub tail); slow-broad-based gait and retropulsion; repetitive movements; (3) generalized tonic-clonic convulsions of 6-20 seconds'
duration; (4) death during convulsion, or the animal may recover gradually, exhibiting the signs of Stage 2 for 8-24 hours while crouched against
the cage wall with eyes open.

Freund reported that 7 of 10 of these ICR-

DUB mice reached the convulsive stage.

Freund ruled out hypoglycemia,

starvation ketosis, and Metrecal diet as sources of convulsions.

In

later experiments, he replaced previous weight reduction with cold-room
environments, (Freund, 1973 ), thus stimulating greater drinking by the
mice.
One critic of Freund's animal model, Mendelson (1971), believes
that malnutrition may in part be responsible for the withdrawal symptoms
seen.

He states that the Freund diet did not make it clear if the mice,

while on 1-12 weeks of alcohol diet, had regained their basal pre-alcohol
administration weight.
The frequency of malnutrition in human alcoholics, is, in part,
associated with social and environmental conditions, states Mendelson.
It is possible that vitamin deficiencies, which are believed to be of
great import in alcohol-related neuropathologies, have been reduced
because of greater availability of vitamin-enriched foods.
The poor dietary intake by alcoholics when they are drinking
cannot be totally attributable to the fact that alcohol, which contains
7 calories/gm, suppresses appetite or replaces a need for other caloric
intake.

Recent studies by Mendelson (1970) and co-workers indicate that
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alcoholics may consciously refrain from eating because they wish to
obtain a better or greater response from a given dose of alcohol.

The

mechanism underlying this phenomenon is related to a decreased rate of
EtOH metabolism that occurs as a consequence of food deprivation or
starvation.

Thus, alcoholics learn that enhanced inebriation can be

obtained through decreased food intake during a drinking episode.

To a

lesser extent, the suppression of appetite due to EtOH also plays a
role in food abstinence.

Mendelson postulated that brain damage in

alcoholics results from a combination of factors -- neuropathophysiological effects of direct EtOH toxicity, food deprivation, and alcohol
withdrawal states -- rather than from a single cause (Mendelson, 1970).
One recent alcohol dependence experiment in the rat involves
gastric intubation.

Wallgren et al (1973) used tert-butanol, primarily

-- --

because it is not oxidized, thus avoiding the complication of its actions
by aldehydes.

The tert-butanol was given to rats twice daily for 21

days along with a liquid diet, the latter to avoid constipation. A state
resembling a severe withdrawal illness was observed when the tert-butanol
was stopped.

Thus, EtOH-like withdrawal symptoms can result after

administration of alcohols other than EtOH.
Mello and Mendelson (1973) maintained monkeys in a rewardassociation paradigm in which a drinking response yielded a dry food
pellet.

The delivery of the pellets is accompanied by consumption of

large quantities of fluid.

However, neither marked intoxication nor ev-

idence of withdrawal signs were seen
polydipsia sessions.

d~ring

six-monthsof daily 3-hour
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PART.TWO
EXPERIMENTAL
A.

MATERIALS
Acetaldehyde-Eastman, redistilled into small vials when needed
and stored at - 20°c.
3 15 1

-

adenosine triphosphate

disodium salt, equine muscle -

Sigma.
Adsorbosil-1

TLC powder - Applied Science Labs.

Aluminum oxide - Grade I Neutral - Woelm.

activated by ·HCl

Ascorbic acid - Lilly
BBS-3 scintillation solubilizer - Beckman
Bovine serum albumin - Sigma.
Carbosieve-B

G.C. column support - 60/80 mesh - Supelco Co.

Cellulose MN 300 TLC plates - Brinkman
Diethyldithiocarbamate - Eastman
DL-3,4-Dihydroxymandelic acid - Grade II Sigma
3,4-dihydroxy phenylglycol - Sigma
3,4-dihydroxytoluene .- Pfaltz and Bauer
2,3-dimethoxyphenol - Aldrich
Disulfiram (antabuse) - Tetraethylthiuramdisulfide - Ayerst
Bis - 2,5-diphenyloxazole (PPO) - Scintillation Fluor - Beckman
Dowex AG-50 Ion-Exchange Resin - Bio-Rad LabsEllagic Acid Dihydrate - Aldrich
Epinephrine HCl - Sigma
Ethanol, 95% - Mallinckrodt
Ethanol, Absolute-Commercial Solvents Corp.
Folin reagent - Sigma
Gallic acid monohydrate - (3,4,5-trihydroxy benzoic acid) Aldrich
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Gas chromatographs - Barber Coleman Model 5320, Varian Model 2100
Gas chromatography glass columns - Lance Glass Works Inc.
Beta-Glucoronidase Type II - Sigma
Heparin Sodium Salt, Grade I - Sigma
1,4-Hydroquinone - Eastman
Ink (recorder) - Applied Science
Ion-exchange glass columns - Ace glassware
Kreb's Ringer's - phosphate buffer - NaCl, KCl, Mgso 4 , 0.154 M
each; Ca Cl2 0.11 M, Na2HP04 buffer pH 7.4 0.1 M. - Mallinckrodt
Liquid scintillation spectrometer, Model LS-250 - Beckman
DL-Methionine - Nutritional Biochemicals Co.
3-Methoxycatechol - Aldrich
Metrecal Shape liquid-Gazzola Drug Co.
Microlance, Blood Lancet - Becton, Dickinson and Co.
Micropipet, 20 microliters - DADE
Beta-Nicotinamide Adenine Dinucleotide (NAD)-Grade II - Sigma
Norepinephrine (Arterenol) HCl - Sigma
7-3H-(DL)-Norepinephrine HCl - International Chemical and Nuclear Co.
DL-Normetanephrine HCl - Sigma
pH Meter - Model 12B-Corning
Planimeter - Gelman Instrument Co.
Porapak Q-S GC Column Support - 80/100 mesh - Waters Associates
Propionaldehyde - Eastman
Propylgallate - Aldrich
Pyrogallol (1,2,3-trihydroxybenzene) - Sigma
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RO 4-4602 - (N' - (DL-seryl)- N2 -(2,3,4-trihydroxybenzyl)
hydrazide

- Hoffmann - LaRoche

(gift)

S-Adenosyl-L-Methionine chloride (70-80%)- Sigma
Salsolinol HBr

98% - K and K Labs

Scintillation bottles and polyethylene-lined screw capsScientific Products.
Septum, G.C. - Applied Science
Serum Bottle 30 cc and Stopper

- Scientific Products

Shikimic acid - Aldrich
Snoop Leak detector soap - Applied Science
Spectrophotometer - Model Acta CIII-Beckman
Syringe, Gas-tight - pressure-Lok A-2 - Pierce
Tetrahydroisoquinolines (4,6,7-trihydroxy)- synthesized by M. Collins,
"
F. Kernozek. (1972).

Tetrahydroxy - 1,4-quinone dihydrate - Aldrich
Toluene, Scintillation Grade - Beckman
1,2,4-trihydroxybenzene - Aldrich
Vanillylrilandelic acid - (DL-4 -hydroxy-3-methoxy-mandelic acid)Sigma
Zero Gases - Argon, Air, Helium, Hydrogen,
Liquid Carbonic

Nit~ogen

- Size lA-
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B. METHODS
I.

IN VITRO CATABOLISM OF TETRAHYDROISOQUINOLINES
Male Holtzman Sprague-Dawley rats, weighing 300-400

gm

each, were

injected with pyrogallol (PG) 250 mg/kg i.p. in 1 ml 0.9% saline or with
0.9% saline only.

One-half hour following pyrogallol or saline injection,

rats were decapitated and livers and brains were removed and washed in
cold Kreb's-Ringer's phosphate buffer pH 7.4.

Homogenization was done

with a chilled Teflon homogenizer in 2 volumes of ice-cold buffer which
contained L-ascorbic acid, 0.5 mg/ml.

To each homogenate containing

500 mg of tissue was added lOOpmoles MgC1 2 (O.l ml), 2 nanomoles ( 1 FC)
of the catechol substrate to be metabolized ( 1 pl), and a self-regenerating COMT cofactor system (Schweitzer and Friedhoff, 1969) consisting
of 5 pmoles each of DL-methi.mine (0 .25 ml), adenosine triphosphate (ATP)
(O.l ml) and S-adenosyl-L-methionine chloride (SAM) (0.1 ml).

The solu-

tions of ATP and SAM were made immediately before addition to the incubate because of their lability in solution.

The total volume of each

incubation mixture was 2.05 ml.
Incubations were carried out in open 25 ml Ehrlenmeyer beakers
in: a 37°C shaking water bath.

Control incubations were either heat-

denatured homogenates (90°c, 5 min) or those without the added COMT cofactors system.

After 2 hours the reaction was stopped by deproteination

with 1 ml 2N HCl and centrifuged at 10,000 g for 15 min at o0 c.
precipitate was washed once with 1 ml 2N HCl.

The

Catechol compounds were

separated from the non-catechol products using an aluminum hydroxide(AH)
slurry method (Cohen, 1971).

The supernatant and wash were combined in

50 ml beakers to which 3 ml freshly-prepared AH was added.
composed of Al 2 (so4 )3·18Hi>,10% w/v adjusted to pH 8.3).

(The AH was
The AH
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suspension was shaken, centrifuged for 15 minutes at 10,000 g, washed
twice in 1 volume 95% EtOH by resuspension and recentrifugation, and the
non-catechol-containing supernatant was saved.

The precipitate was then

dissolved in 2 ml 4N HCl for 30 minutes, and the aluminum ions reprecipitated as aluminum phosphate by adding 1 ml kH2Po 4 and adjusting to pH
3.5 with lN NaOH.
natant.

This step frees the catechol compounds into the super-

After addition of 4 volumes of acetone: absolute EtOH (1:1 v/v),

centrifugation is done for 20 minutes, the precipitate being resuspended
and recentrifuged.

The final supernatant

had

contained the free

catechols, as confirmed by thin layer chromatography (vide infra).
The radioactivity of a 1 ml aliquot of each fraction was measured
in a solution of toluene: 2,5-diphenyloxazole: BBS-3 (Beckman; 100 ml:
5 gm: 200 ml) by liquid scintillation spectrometry on a Beckman LS-250
spectrometer.

Thin-layer chromatography (TLC) with zonal scraping was

carried out on aliquots of the fractions using the conditions described
below for the 3 H-TIQ sub~trates.

Recovery was 70 ± 5%.

The substrate TIQs were produced in lM NaOAc pH 6 buffer by
condensation of 7-3H-d,l-NE with excess aldehyde, as described by Cohen
and Collins (1970).

Reaction with pre-distilled AcD gave as the major

product, l-methyl-4,6,7-trihydroxy-1,2,3,4-TIQ (TIQ I,), while formaldehyde (HCHO) yielded 4,6,7-trihydroxy-1,2,3,4-TIQ (TIQ II) (Fig. 1

)

The extent of reaction was determined by iodochrome monitoring and by
TLC.

todochrqne monitoring consisted of oxidizing open-chain amines

(e.g. CAs) with iodine to a pink color,. while cyclized amines such as
TIQs turn yellow in solution.

Aqueous solutions (2.5 cc) of each com-

pound (1 mg/ml) were tested at pH 7.0 by addition of 0.1 ml Na 2s2 o3 0.05N
followed in two minutes by 0.2 ml Na s2 o 0.05 N.
2
3

The TIQs were then
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separated from unreacted aldehyde by adsorption on aluminum oxide (Al 203)
columns at pH 8.3) washing twice with distilled water) followed by elution with lN HCl.

The eluates

were subjected to TLC

w~th

w~re

then readjusted to pH 7.4 and again

zonal scraping for proof of purity, prior to

addition to the homogenates.

3 H-NE was prep~rified on Al o in the same
2 3

manner.
TLC glass plates (20 x 20 cm) were coated with 0.25 mm Adsorbosil1, air-dried 20 minutes, and heat-activated for 30 minutes at ll0°c.
Development was in sec-butanol: formic acid: water (15:3:2) under nitrogen atmosphere in a tank lined with solvent-saturated filter paper (TLC
System A).

A second TLC system (TLC System B) was also employed, using

Brinkman cellulose MN 300 plates, 0.5 mm thick, developed in methanol:
n-butanol: benzene: water (40:30:20:10).
potass~um

Visualizing spray reagents were

ferricyanide (4,4 mg/ml in 0.2 M phosphate buffer, pH 8.3) fol-

lowed by ferric chloride (2.5% in water freshly mixed with 1.5 volumes
of acetone).

Unlabelled TIQ standards were co-chromatographed with the

radioactive reaction products.

These standards had been synthesized in

this laboratory by established organic procedures and their identities
confirmed by elemental analysis and nuclear magnetic resonance (Collins
and Kernozek, 1972).
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II.

IN VIVO ACETALDEHYDE AND ETHANOL BLOOD LEVELS
Non-fasted Holtzman Sprague-Dawley rats (300-400 gm) were given

EtOH ( 2 gm/kg i.p.; 25% v/v) 1 hour after pyrogallol (PG) or saline.
Tail blood samples (20 1ul) were taken at various intervals after EtOH
injection by cutting the distal inch of the tail with a razor blade and
milking it.

AcD and EtOH blood levels were then estimated on a Barber-

Coleman 5320 flame ionization gas chromatograph (GC) by the method of
Coldwell~

al (1971).

In this technique, 2 cm square disks of #1

Whatman filter paper were soaked in 0.2% sodium fluoride and then airdried.

After placement of disks in 30 cc serum bottles, blood .samples

were blown into the disks from heparinized 20;ul pipettes.

With the

pipette left in, the bottle was then closed with a rubber septum-centered
stopper.

Equilibration of vapors was achieved in a shaking water bath at

35°c for 15 minutes.
As the modifications of the GC technique, 2 cc headspace gas
samples were injected into the GC, and 6' x

~"

metal columns packed with

Porapak QS (80/100 mesh, Waters Associates) were used.

Conditions

employed for Porapak were gas flows (ml/min) for nitrogen, hydrogen, air,
100, 30, 300, respectively; column temperature, 1450C., injector temperature, 200°c; detector temperature, 210°C; retention times were determined
(Fig 2

).

All other compounds tested for their effect on EtOH and AcD levels
were injected into the animals in the same manner as PG, being dissolved
inunediately before injection in distilled water, in order to minimize any
changes in aqueous solution.

r
'
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III. IN VITRO DISAPPFARANCE OF ACETALDEHYDE
Before testing for inhibition of the semi-purified ALDH, and
exploratory experiment was perfonned to examine whether pre-injection
with PG would decrease the rate of disappearapce of AcD added to rat
liver in vitro. AcD 0.33 mM and NAD 0.33 mM were injected through the
rubber stopper of a 30 cc serum bottle containing 1 ml rat liver homogenate (1:1 v/v in pH

7~4

sodium pyrophosphate 0.1 M).

The liver tissue

was obtained from rats injected one hour pre-sacrifice with PG (250 mg/kg)
or saline (control).

Incubation of the homogenate was for 30 minutes in

a 37°c. shaking water bath.

Samples of vapor were taken at 5, 10, 15 and

30 minutes and measured by gas chromatography.

level of AcD at 30 minutes was subtracted

For each sample, the

from the maximal level of AcD

observed.
This experiment was conducted to determine by gas chromatography
if AcD disappearance (oxidation) was slowed by in vivo PG.

The results

indicated that indeed it was, thus substantiating the in vivo experiments
with injected AcD, reported by Collins et al, 1974
seemed

f~asible

Therefore, it

to further examine liver ALDH (vide infra).

r
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IV.

IN VITRO ASSAY OF ALDEHYDE DEHYDROGENASE*
The intramitochondrial assay for ALDH was done using the method

of Dietrich and Erwin (1971) •

Immediately after the decapitation of

four male Holtzman rats weighing 350 gm each, the livers were removed
and cut into small pieces, fibrous structures being removed at this time.
All procedures were carried out at or below 4°C.

The tissue was made

into a 10% v/v homogenate in 0.32 M sucrose with 10 strokes of a teflon
homogenizer.

After centrifugation for 10 minutes at 750xg in 50 cc poly-

allomer tubes, the precipitate was discarded and the supernatant was
centrifuged at 20,200xg for 15 minutes.

The resulting supernatant was

discarded and the mitochondrial pellet resuspended to the original volume
by manual homogenization with the teflon homogenizer.
20,200xg for 15 minutes was again done.
to a final volume of 100 ml in 0.05M

Centrifugation at

The precipitate was resuspended

NaH2P04 pH 7.4.

This mixture was

sonicated in a 250 ml beaker for four 1-minute periods with 3-minute
cooling intervals between each, using a Branson sonifier model LS-75,
setting 7, amperage 7.

The sonicate was centrifuged at 37,000xg for 15

minutes, saving the clear supernatant at

o0 c

for the ALDH assay.

The assay was conducted using a Beckman ACTA Clll Recording
Spectrophotometer, the absorbance of the NADH formed from NAD being
monitored using the tungsten lamp at a wavelength of 340 nm.

Settings

were as follows: dynode voltage 600, scan speed 1 run/sec., chart expansion 50 nm/inch, span 0.1, dwell 2.5 sec., interval 15 sec., shutter
standard and reference open •
The concentration of protein in the enzyme preparation was performed according to Lowry ( 1962).

The reagents used were: (A) Na 2co 3

* Carried out in the laboratory of Dr. Boris Tabakoff, Dept. of
Biochemistry, Chicago Medical School.

r

52

2% in 0.1 N NaOH; (B) Cuso 4 . HzO

0.5% in 1% sodium citrate; (C) reagent

(B) 1 ml plus reagent (A) 50 ml; (D) Folin commercial reagent diluted
with water to give a solution of lN.

To each test tube is added 0.05 ml

sample,0.65 ml water, and 1 ml reagent C.

The tube is mixed by vortex

and is left at room temperature for 10 min.
rapidly to each tube which is vortexed.

Reagent D (O.l ml) is added

Samples may be read after 30 min

at an excitation wavelength of 750nm on a Beckman Acta Clll spectrophotometer.

Control samples were, made from solutions of bovine serum albumin.
All solutions were kept in ice immediately after preparation.
The assay mixture contained 0.2 ml enzyme (0.50 mg/ml),0.1 ml

inhibitor, and the following components given with their final concentrations: 0.1 ml NAD 0.001 M, 0.1 ml NaH

2

Po4

0.05M pH 7.0, 0.1 ml propion-

aldehyde substrate 0.002 M, brought up to a final volume of 1.0 ml with
distilled water.
Although the pH optimum for ALDH is 9.6-10.0, the pH of 7.0 was
used to minimize the oxidation of PG and other compounds tested for
inhibition.
(3-minute

The slight oxidation of PG that occurs in the first 5 min
warm-up time and 2-minute reaction time) was substracted by

using a control sample containing PG with no propionaldehyde substrate.
Most of the oxidation of PG in the 25°c experimental conditions used
seemed to occur after 10 minutes, as evidenced by an increasing peak of
absorbance at the wavelength setting used.

This, however, occurred too

late to affect the experimental results.
Quartz cuvettes of 1.5 ml volume were used, being rinsed once
wi~i1

EtOH and thrice with water after each reaction.

After a 3-minute

adaptation period in the dark at 25°c in the machine, the reaction was
started by the addition of propionaldehyde, followed by mixing each

r
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reaction twice with a clean Pasteur pipette.

The maximum velocity in

O.D. units for the first 100 seconds of reaction time was recorded, and
converted into moles NADH/min/mg protein by using the conversion factor
of 32.8 x 10

-9

•

This conversion factor included the extinction coeffi-

cient for NADH, which is 6220 moles per liter.

The average velocity of

three samples at each concentration of inhibitor, while varying NAD and
propionaldehyde concentrations, was computed and plotted in a double
reciprocal graph of velocity versus substrate concentration (Lineweaver
and Burk,

1934).

Linear regression analysis, computed on an Olivetti

Programma 101, gave the corresponding values of l/Vmax and -1/Km.
The structures of compounds tested for inhibition of ALDH are
shown in Fig. 12.

54

v.

CHRONIC ALCOHOL DRINKING MODELS
The animal model used here for voluntary alcohol ingestion was

reported by Freund in 1969 using mice.

The diet is shown in Table 1.

Two hundred male ICR-DUB mice (Scientific Small Animals Farms)
weighing 25-35 gm, were housed

separatelY'~,

given daily water and 1.5 gm

of Purine rodent lab chow (about 1/3 normal voluntary intake).

After

nine days, weights were found to be reduced 25-30%, and animals were
then started on a diet of ad lib EtOH in Metrecal or on isocaloric
sucrose-Metrecal solution, either diet being the sole source of food.
Animals were observed for gross signs of intoxication for 5 days, at
which time they were withdrawn from EtOH-Metrecal diets onto isocaloric
sucrose-}fetrecal diets.
withdrawal.

They were then sacrificed after 1-2 days of

Animals had been graded behaviorally as to their degree of

intoxication and withdrawal severity, as shown in Table 2.

Animals were

sacrificed at the proper times to represent each of the following groups:
(1) weight-reduced, (2) weight-reduced plus intoxicated with EtOH, (3)
weight-reduced, intoxicated, plus withdrawn onto sucrose, (4) weightreduced plus sucrose feedingfur the entire experiment, and (5) controls,
which were fed lab chow ad lib and then sacrificed before weight-reduction
or special diets.
Since it was discovered that EtOH-drinking mice (Tables 12 and
14) drank a lesser daily volume and regained less of their reduced weight

*

Performed in the laboratory of Dr. Charles Scudder, Loyola University
of Chicago.
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than did the sucrose drinkers, it was decided that pair-feeding would be
conducted in the next experiment, which involved rabbits.

This involved

measuring the daily intake of the EtOH-drinkers drinking ad lib, and
then feeding no more than that amount to the sucrose controls on the
following day.

Thus, the question of differential nutrition between

the experimental and control groups would be ruled out as a source of
problems.
Ten-week-old male New Zealand white rabbits were housed singly
and for one week were fed water and Purina rabbit chow ad lib.
For 80 days, six animals were fed liquid diets as the.sole
source of calories. Cage bottoms were of mesh, allowing feces to fall
from the cage and not be reingested. EtOH diets were composed of
Metrecal Shape chocolate drink plus 95% EtOH.

The three corresponding

control animals were given isocaloric sucrose substituted for EtOH, and
each was pair-fed the average volume of diet consumed by the three
experimental animals on the previous day. Freshly mixed food was offered daily in pottery bowls to avoid the problems previously encountered: spoilage, which occurred to some extent with the mouse experiment, and tube plugging due to sedimentation, which also occurred frequently in the mouse experiment, even with larger-bore tube openings,
thus precipitating withdrawal or starvation as a complication of
technique.

Gas chromatographic testing of the EtOH-Metrecal solutions

in open pottery bowls showed negligible loss of EtOH to evaporation over
24 hr at room temperature.
Blood samples were taken from the ear vein of each rabbit,
including controls, at about 11 A.M. daily or every other day.

The

samples were then measured for concentrations of EtOH and AcD with the
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flame-ionization detector of the Barber-Colman GC Model 5320 as described
previously for rat experiments.
Animals were changed to clean cages weekly.

Cage-cleaning,

feeding, blood-sampling and weekly weighing were all performed in a
random order among the animals in order to minimize differences in
handling.
Each experimental animal drank EtOH-Metrecal ad libitum from
500 ml daily servings, which none of them over completed.

In this diet,

EtOH initially comprised 35% of the calories, or 6.0% volume/total
volume (v/tv) concentration.

The EtOH concentration was slowly

increased by steps over eighty days until it reached 20% v/tv, or 71%
of total calories (Table 14).
All animals were allowed to eat until the end of the experiment,
and thus withdrawal effects were not sought.

After 80 days, animals

were sacrificed by decapitation and the livers removed, washed and
placed in formalin.

Livers were then sectioned for light microscopy

and stained with hematoxylin and eosin.
As the results indicate, only minimal intoxication was seen, so
attempts to induce withdrawal seemed futile, contrary to the mouse
experiment.
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RESULTS
A.

SYNTHESIS AND THIN-LAYER CHROMATOGRAPHY OF TETRAHYDROISOQUINOLINES
Table 3 shows the results of iodochrome monitoring of CA-

aldehyde condensation reactions.

The reaction times for HCHO plus CAs

were several times faster than those for AcD plus CAs. NE reacted more
rapidly with either aldehyde than did EPI.

The fastest reaction was

that of NE plus HCHO (5 minutes), while EPI took 35 minutes to completely react with AcD at the conditions used.
The results of thin-layer chromatography of NE and related compounds are listed in Table 4.

Two separate solvent systems were

employed to confirm the results. Standard compounds included NE, its 30-methylated product normetanephrine (NM), TIQ I (NE-AcD), TIQ II (NEHCHO), and the 6-0-Methylated products for each of the TIQs. The degree
of migration was measured by Rf, the ratio cf the distance between the
compound and the origin, divided by the distance between the solvent
front and the origin.
From the highest to the lowest migrating substances, the results
were: System A, NM, 6-0-Me-TIQ I, NE, TIQ I, 6-0-Me-TIQ II, and TIQ II;
System B, NM, TIQ I, 6-0-Me-TIQ II, 6-0-Me-TIQ I, NE, and TIQ II. With
the exception of TIQ I on System B, each catechol compound was separated
from its corresponding 0-methyl compound by an Rf value of 0.06 to 0.10.
B.

IN VITRO CATABOLISM OF TETRAHYDROISOQUINOLINES
The in vitro catabolic products of 3H-NE or 3H-TIQs were studied

following the two hour incubation.

A decrease in adsorption of radio-

active label to the catechol-binding Al20 3 column indicated a conversion
to non-catechol metabolites.
Metabolism of the two TIQs was qualitatively different from that

r-
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of their NE "precursor."

Non-catechol portions from incubations of brain

or liver tissue with TIQ II consistently showed only one radioactive TLC
zone which co-chromatographed with a synthesized standard of the expected 0-methylated metabolite, 4,7-dihydroxy-6-methoxy-TIQ.

Similarly, non-

catechol effluent from incubations of TIQ I with either tissue demonstrated a single radioactive zone-co-chromatographing with a synthetic standard of the expected l-methyl-6-0-methylated product (Fig. 10).
When examined by TLC, the non-catechol portions from NE incubations, contained radioactive normetanephrine and radioactive 0-methylated
products migrating with standards of 3-methoxy-4-hydroxyphenylglycol and
vanillylmandelic acid; these deaminated non-catechol products are included in the total percentages for NE products in Table 5.
For either TIQ, the catechol portions contained radioactivity
apparently associated only with unreacted substrates.

Thus, it appeared

in these studies that formation of possible products of MAO action on
these TIQs, as had occurred with NE, was insignificant for these alkaloids.
As shown in Table 5, 0-methylation in brain homogenates proceeded
to a similar degree for all three catechol substrates.
(21.5

± 6.1%),

NE (33.6

Metabolism of TIQ I

however, was slightly but significantly less than that of

± 4.6%).

Liver, on the other hand, was found to metabolize

these substrates in a somewhat reverse order, TIQ I > TIQ II > NE
(78.2 + 8.3, 58.l

± 4.5

and 35.3

± 4.6%,

respectively).

Comparing the two TIQs, the AcD-derived TIQ I was a better substrate for liver COMT than was the HCHO-derived TIQ II, while the two
were not appreciably different in brain tissue.

Pyrogallol inhibited

the 0-methylation in liver of TIQ II (89.4%) more than that of TIQ I
(60.4%), but the relative extents of inhibtion were reversed in brain
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tissue (TIQ I,90.7%; TIQ II; 73.1%).

(Fig. 3 and 4)

The conversion in vitro of the substrates to glucuronide products
~vas

apparently ruled out by incubation of the homogenate products with

B-glucuronidase for 4 hours resulting in no change in the TLC and column
radioactivity patterns.

Possible oxidation of the substrates to quinone

products was countered by the addition to the incubation mistures of
ascorbic acid.

r
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c.

EFFECT OF PYROGALLOL ON IN VITRO ETHANOL AND ACETALDEHYDE
BLOOD LEVELS
Using the microtechnique described (vide supra), separation of

AcD, EtOH, and acetone was attained on a Porapak QS column (Fig. 2).
Relative retention times were as follows: AcD 1.0, EtOH 2.1, Acetone 2.6.
Peak heights were found to be directly proportional to peak
volumes (measured by planimetry) in the concentrations used, so that
peak heights were used for conversion to AcD or EtOH concentrations.
Figure 5 shows Porapak calibration curves prepared for the estimation
of blood AcD and EtOH, respectively.

Acetone was not seen in the blood

of rats injected with EtOH or AcD,although it has been reported to
exist under such conditions (Coldwell et al, 1971).
Table 6 illustrates the effect of PG pre-injection on the in vivo
blood levels of AcD and EtOH in rats injected with EtOH 2.0 g/kg.

PG

potentiated the AcD levels, the concentrations, of AcD being increased
significantly (p < 0.05) at 60, 120, 180 and 270 min.

Comparing saline-

injected rats to PG-injected rats, the AcD blood concentrations at these
times were increased (pg/ml) by PG from 2.6 ± 0.5 to 4.8

± 1.2, from

2.0 +
- 0.4 to 4.1 +
- 1.6, from 1.0 +
- 0.2 to 3.6 +
- 1.2, and from 0.3 +
- 0.1

+

to 1.9 - 0.4, respectively.
EtOH levels were increased slightly by PG, from a maximum saline
level of 1700 +- 400 pg/ml to 1900 +- pg/ml.

The increase of EtOH

concentration caused by PG was not significant when the saline and PG
values were compared either maximum vs. maximum (1700 vs. 1900) or time
vs. time (60 minutes saline vs. 60 minutes PG, 120 vs. 120, etc.
The administration of PG to rats was noticed to result in darkening of the blood from the normal bright red color seen following saline
injection, to dark red, purple or reddish-brown.
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D.

EFFECT OF PYROGALLOL, PYROGALLOL ANALOGUES AND METABOLITES, AND
DIETHYLDITHIOCARBAMATE ON ALDEHYDE DEHYDROGENASE IN VITRO
The results of a preliminary screening experiment on the effect

of PG on AcD metabolism in vitro is shown in Fig. 11.
appearance of AcD in rat liver was

diminishe~

The rate of dis-

after pre-injection with PG.

The AcD peak height was significantly increased (p

<

0.01) by PG at 15

and 30 minutes.
A sample spectrophotometric recording of the ALDH assay is shown
in Fig. 6, denoting typical results seen upon testing an inhibitor of
the enzyme.

The effect of PG on ALDH activity in vitro is demonstrated

in the two graphs of Fig. 7 and 8.

The double reciprocal plots of

activity versus NAD or propionaldehyde concentrations indicate a mixed
inhibition by PG with respect to both compounds.
The binding of PG was reversible, as demonstrated by the dilution
method.

Aliquots of PG plus enzyme which were allowed to stand for 5

minutes to permit possible binding of PG to enzyme, and were added to
the assay mixture.

Thus, if PG were irreversibly bound to enzyme, the

PG-enzyme aliquot would not inhibit the assay activity.
evidence for irreversibility was not seen (Table 7).

However, such

Instead, PG-enzyme

aliquots added to the assay caused inhibition of activity equal to the
inhibition caused by the same concentration of PG added alone.

Thus,

the binding of PG was apparently of the reversible nature.
Various control samples were employed to demonstrate the verity
of the observed inhibition by PG (Table 7).

Several samples contained

all assay components except one, ruling out artifactual results.

Other

samples were pre-incu.bated with PG for 3,5,10 or 15 minutes at room
temperature before propionaldehyde was added, as compared to the normal

,,....-
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3 minute warm-up to room temperature.

The results from these samples

showed that pre-incubation for up to 15 minutes does not effec the
inhibition of ALDH by PG.

Thus, a possible inhibitory role for an

aqueous degradation product of PG is apparently disallowed.
In Table 8, the effect on ALDH of PG'and structural analogues
is seen.

The strongest inhibitors appear to be PG, 1,2,4-trihydroxy-

benzene, hydroquinone, RO 4-4602, diethyldithiocarbamate and 3-methoxycatechol, all of which caused

> 15% inhibition at 5 x l0- 4M.

The

remaining compounds, gallic acid, 2,3,-dimethoxyphenol, propylgallate,
shikimic acid, 3,4-dihydroxytolvene, and tetrahydroxyquinone, inhibited
either mildly or not at all.
Table 9 compares the effects of various drugs on ALDH activity
in vitro, to their in vivo effects on EtOH-derived AcD blood levels.
PG, DDC, and RO 4-4602 were both in vitro inhibitors and in vivo
potentiators in these experiments, while hydroquinone, 3-methoxy-catechol
and 1,2,4-trihydroxybenzene had in vitro but not in vivo effects.

Gallic

acid and 2,3-dimethoxyphenol had no observable effects on either system.
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E.

CHRONIC ALCOHOL DRINKING MODELS
1. MOUSE EXPERIMENTS
The behavioral effects on male mice of ingestion cf the EtOH-

Metrecal diet are indicated in Table 2.

All animals became intoxicated

to some degree, approximately one-fourth reaching the ataxic stage,
one-fourth the comatose stage, and one-half achieving intermediate
severity of intoxication.

The study of Freund (1969), by comparison,

resulted in only intermediate and maximal stages of severity of intoxication, with 50% of animals in each group.

All of Freund's animals

surpassed the initial ataxic stage of intoxication.
A major behavioral difference in the two studies on mice was in
the extent of withdrawal symptoms observed, as shown in Table 2.

None

of the mice died during convulsion, as opposed to 10% of those of
Freund; in fact, only one of the 28 mice in the experimeris described
here even reached the convulsive stage, compared to 60% of Freund's
animals that had tonic-clonic convulsions.

The second stage of with-

drawal, that of tail-beating, etc., was achieved by 2 of 28 and 3 of 10
of the mice in this study and Freund's study, respectively.

Both of

the animals reaching the second stage of withdrawal in our experiment
exhibited tail-beating, stereotypy, retropulsion, broad-based gait and
the tail-to-nose maneuver, the latter

commonly known as the "Straub tail'.'

Possible toxicities or hyponutritive qualities of the Metrecal
diets were examined by measuring the weight changes (Table 10) and the
number of deaths (Table 11) during chr6nic Metrecal drinking in mice.
Approximately 3% (5 of 180) of mice died during the phase of 25-30%
weight reduction before the Metrecal diet was instituted.

Another 8
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animals expired during the five days of drinking the EtOH-Metrecal combination.

Three of these animals died with their limbs extended, pos-

sibly denoting death during convulsion, according to Freund (1969).

No

mice died during the withdrawal of EtOH onto isocaloric sucrose or while
on the sucrose-Metrecal diet that followed weight reduction.
The change in the weights of mice while on the two Metrecal diets
is shown in Table 12.

Measuring the change in body weight from the end

of the weight reduction period to the end of the Metrecal regimens, the
EtOH group was seen to lose an additional 4.4% while those drinking
sucrose regained 14.6% of their weight.
The daily volume of Metrecal diet consumed ad lib by mice, in
Table 13, shows a doubling of consumed liquid diet by the sucrose group
compared to the consumption of the EtOH group.

r

65
2. RABBIT EXPERIMENT
In the rabbit experiment, EtOH consumption (Table 14) almost
doubled following the gradual doubling of EtOH-derived calories from
35% to 71%.

The greatest changes in consumption were seen to occur in

the lower ranges of EtOH concentration.

Increasing EtOH from 6.0 to

7.5% v/v and from 7.5 to 10.0% v/v caused the highest changes of about
5-6 ml/day.

Concentrations of EtOH above 10.0% did not contribute as

much to an increase in consumption.
Table 15, indicates the physical changes seen while the animals
were fed either of the liquid diets.

Massive loss of body hair was

seen in two-thirds of both the EtOH- and the sucrose-drinking groups.
The hair loss was heaviest on the underside and on the legs, and began
to occur within 14 days after the experiment was begun.
basis may have existed for this hair loss, since·

A nutritional

fur mites could not

be detected from microscopic examination of skin scrapings from affected areas of any animal performed by Dr. Fred Buddingh of the Animal
Research Facilities, Loyola University.
Weight loss or sub-normal weight gain was seen in both the EtOH
and sucrose groups (Table 12).

Actually, five of these six animals

gained a small percentage of their original ten-week-old weight during
the 80-day experiment.

However, their litter mates eating normal lab

chow and water ad lib increased their body weights by 70%.
The· only death occurred in a sucrose control rabbit on day 76.
This animal had shown extensive hair loss over a period of weeks and
finally became listless and ceased to eat 2 days before its death. None
of the ethanol-treated animals expired (Table 11).
Gross intoxication was never observed in the ethanol-drinking
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rabbit (except for a few days early in the experiment).

Animals were

observed inside and outside of the cages for ataxia and for stuporous or
comatose qualities.
a) Blood levels of ethanol and acetaldehyde
Ethanol and acetaldehyde blood levels are shown in Fig. 9
Neither compound was ever observed in the blood of sucrose animals.

In

the ethanol group, ethanol levels ranged from 0-100 mg/100 ml of blood
(mg%) during most of the experiment, although the blood ethanol of animal 1 rose to 200-400 mg% while drinking the 10.0% ethanol solution and
returned to normal within 10 days.

It was during this period that we

observed increased ataxia, daytime eye-closure, and warmth and redness of
the ears in this animal.
The pattern of blood acetaldehyde levels usually resembled the
blood ethanol variations, the acetaldehyde fluctuating from 0-30 pg/ml
but usually below 9 ,ug/ml.

However, when 17 .5/, and 20.0% ethanol solu-

tions were fed to the animals, large increases occurred in the blood
levels of both EtOH and AcD.
b) Liver Pathology

(Figs. 13 and 14)

Hematoxylin - and eosin - stained liver sections performed by
Dr. Buddingh, showed severe fatty changes throughout the livers of animals on the EtOH-Metrecal diet.

The livers of sucrose-Metrecal-fed an-

imals displayed negligible or no fatty change, while the animals on
normal lab chow had normal hepatic architecture.
ogy, such as hepatocyte swelling, was observed.
was performed.

No other hepatic patholNo electron microscopy
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DISCUSSION
A.

OVERVIEW
These studies were concerned with several related aspects of

the biochemical bases of alcohol dependence.

TIQs, hypothesized to be

aberrant CA "metabolites" during alcoholism, were investigated as in
vitro
MAO.

substrates for the important CA-metabolizing enzymes, COMT and
Secondly, when in vivo rat intoxication experiments were initiated,

it was noted that PG pre-injection caused AcD blood levels to be significantly elevated.

The mechanism of this elevation was explored briefly

, in vivo and in greater detail in vitro with purified rat liver ALDH.
Concurrently, chronic alcoholic mouse and rabbit models were studied.
Various parameters were gauged in these studies, including signs
of gross intoxication, rabbit liver cytoarchitecture, and rabbit blood
levels of AcD and EtOH.

r
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IN VITRO CATABOLISM OF TETRAHYDROISOQUINOLINES

B.

In the TIQ cataboli'c experiments with liver tissue, a-methylated
products derived from NE were always formed to a lesser extent than were
a-methylated products from either TIQ.

These findings were in accord

with the report of the metabolism by rat liver COMT of the l-methyl-6,7dihydroxy-TIQ, salsolinol (analogous to TIQ I without the aliphatic
hydroxy group).

A. Collins et al (1973), found salsolinol to be a better

substrate in vitro for COMT than the parent amine, DA.

Salsolinol was

also seen to serve as a moderate competitive inhibitor of COMT in vitro
(A. Collins et al, 1973).

In our work, a further observation can be made

that the 1-methyl group of TIQ I seemed to increase 0-methylation in
liver compared to TIQ II, but made no significant difference in the brain
metabolism of the two alkaloids.

Although TIQ I is methylated on the

1-carbon atom, it is a 2° amine; our results can be compared to those of
Creveling et al (197a) which indicated a higher affinity of COMT for the
2° amine ,E, than for the 1° amine, NE.

However-, .Axelrod and Tomchick

(1958) found the substrate specificity of COMT to be roughly equal for E
and NE.
Pyrogallol inhibition was quite variable in its extent and was
never complete.

In an earlier work by Crout (1961), 90-100% inhibition

of semi-purified COMT was achieved after injection of PG 200 mg/kg, some
50 mg/kg below our level.

PG inhibition of COMT in our system never

reached 100%, possibly for some or all of the following reasons: (1) PG
is itself a known substrate for COMT and was partially consumed during
the experiments;

(2) PG may be oxidized to an inactive quinone during

the long incubations, despite the addition of ascorbic acid; (3) different
COMT

isoenzymes act in both tissues and respond differently to the
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inhibitor (although

Rock~

al (1970) reported this not to be the case);

(4) other 0-methylating enzymes which are PG-insensitive acted upon the
substrates; or (5) endogenous activators of COMT or inhibitors of the
actions of PG might have been present in the homogenates.
It was also noted that inhibition of 0-methylation was consistently 10%-40% greater for the TIQ substrates than for NE.

Differences

in the relative affinities of the various substrates and their respective
products for the COMT-SAM complex may be responsible for this latter
effect.
Although 6-0-methylation was apparently seen and is expected
because of the analogy to the predominant meta-0-methylationF.i.g.12 of the
parent CAs cited in the literature, 0-methylation of the TIQs on the 7rather than the 6-hydroxyl group is possible.

Creveling

~

al (1972)

have reported 7-0-methylation of (DA-related) 6,7-dihydroxy-TIQs by highly purified COMT preparations.

In order for a 7-methoxy-4,6-dihydroxy-

TIQ to have been present in our homogenates, its TLC migration would
have to be identical to that of its 6-0-methyl isomer, which is possible.
A. Collins et al (1973) also commented on the lack of separation of
various TIQs by TLC. However, the possibility of 7-0-methylation of the
4-hydroxylated (NE-derived) TIQs should be examined with gas chromatographic systems which separate the 6- and 7- isomers.
It has been mentioned in Results

that MAO action on these TIQs

appeared to be insignificant in our homogenates.

However, the product of

MAO action on TIQs is unknown, whether it be ring-breaking to allow
deamination or some other means.

But one simple TIQ thus far, salsolinol,

has been reported to inhibit MAO competitively (A.
as has a tetrahydro-beta-carboline (Mc Isaac

g_t.

Collins~

al, 1972).

al, 1973),

The question
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of whether these compounds are structurally altered during this competition remains to be determined.

It is possible that MAO products of TIQs

did form under our conditions and co-migrated with other TIQs, thus
mask~ng

their identity.

It was our original intent to look for such

products of TIQs, but unfortunately the structures of such postulated
products or intermediates are presently unknown, and thus the organic
synthesis of standards was not attempted.

More than likely, however,

added oxygen, the limitirg factor reported for MAO by some investigators
(Achee et al, 1972), was possibly necessary to allow maximum MAO activity
~lthough

the presence of deaminated metabolites of NE in our system was

evidence for the existence of some MAO activity in our homogenates).
In the studies reported here, the formation of an 0-quinone from
a 4,6,7-trihydroxy-TIQ by non-enzymatic oxidation was probably eliminated
by the addition of the antioxidant, ascorbic

Moreover, simple

ac~d.

quinone standards were found to migrate close to the origin in the TLC
systems used, and little radioactivity was seen in that area.

Conjuga-

tion by glucuronyl transferase can also occur, theoretically, but only
in vivo, according to Axelrod (1958)
systems require cofactor addition.

, since they found that in vitro
In support of this, the incubation

of our homogenate products with beta-glucuronidase produced no clear
changes in the TLC or column radioactivity patterns.
In regard to exploratory in vivo studies, the facile 0-methylation of CA-derived TIQs should be taken into account by investigators
concerned with TIQ detection and isolation •.

Difficulties experienced

in detecting TIQs in vivo could be due to their active conversion to 0methylated (and perhaps conjugated) metabolites.

Indeed, gas chromato-

graphic studies by Bigdelli and Collins,(1973) show that, in rats acutely
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intoxicated with EtOH, TIQ derivatives are detectable in brain and
adrenal tissue when COMT is inhibited and AcD is elevated with PG.
Physiologically, such CA-aldehyde condensation products may
enhance NE and DA activity by acting as competitive COMT inhibitors
or by reducing available COMT cofactor, SAM.

Single doses of L-DOPA

have been reported to act in the latter manner, that is, as a cofactor
depletor (Wortman et al, 1970).

Hence, a metabolic relationship might

exist between the formation of TIQs from aldehydes and CAs, and certain
neurological aspects of chronic alcohol toxicity or of the alcohol
withdrawal syndrome.
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C.

PYROGALLOL AND IN VIVO ACETALDEHYDE AND EtOH BLOOD LEVELS
The mechanism by which PG potentiates blood AcD levels following

injection of EtOH or AcD may be a complex one.

Several possibilities were

_examined, leaving us with the belief that inhibition of ALDH was a logical mechanism, even though PG had never before been reported to possess
such a property.
Among the possible mechanisms of AcD potentiation, it was first
thought that the primary known property of PG, (1) COMT inhibition, was
predominant reason.

Possibly an indirect mechanism of action of PG, that

of inhibition of COMT and subsequent competitive inhibition of aldehyde
dehydrogenase by the presumably potentiated catecholaldehydes, was at
the root of the AcD elevation.

Since in vivo detection methods for the

catecholaldehydes are not yet developed, direct evidence of their potentiation was not achievable.

However, administration of other known COMT

inhibitors -- tropolone, pyrocatechol (Molinoff and Axelrod, 1970), and
3,5-dihydroxy-4-methoxybenzoic acid (Nikodejevic et al, 1970)-- was found
to have no significant effects on AcD levels.

Thus, inhibition of COMT

appears to be unrelated to the ability of PG to elevate EtOH-derived AcD
levels (Collins et al, 1974).

(2) I t was considered possible that the

0-methylated products of PG, 3-methoxycatechol and 2,3-dimethoxyphenol
(Archer et al, 1960), may be the actual elevators of AcD blood levels.

--

However, these compounds did not affect blood AcD when given one hour
before the administration the-EtOH. (3) A possible quinone oxidation.
product of PG could be active in affecting AcD levels.

PG is known to

oxidize in aqueous solutions at room temperature, especially at alkaline
pH.

Thus, the effect of hydroquinone pre-injection was examined, but

this compound was also ineffective in elevating EtOH derived AcD.

There-
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fore, if PG is converted to any appreciable extent in vivo to the
quinone fonn, it was probably not in this fonn that PG exerted its action on AcD levels. Purpurogallin was not tested in vivo.
(4) Another possibility considered was an anti-oxidant or a
general cytotoxic effect of PG.

It seems unlikely, however, that PG

would specifically affect the oxidation of AcD without slowing that of
EtOH as well.

As for the idea of cytotoxicity, the activities of EtOH

catabolic enzymes seemed unaffected, since the EtOH turnover pattern
appeared to be unchanged by PG pretreatment.

Furthennore, Crout et

!!!

(1960) examined . the metabolism of tyramine, which is metabolized by
enzymesother than COMT, and found that PG pretreatment appears to have
no general cytotoxic or omnienzyme-inhibitory power.
(5) PG potentiation of blood AcD levels may be via stimulation of
EtOH oxidation.

PG is suspected to be a potent H2o2 -stimulating agent

in aqueous solution (Heikkila, 1972).

EtOH oxidation via hepatic catala-

se, "peroxidatic oxidation ," (Thunnan et al, 1972; Oshno
would be stimulated by this newly-generated cofactor H2o2 •

§!.·al, 1973)
If modulation

of catalase activity is involved, PG may be an important drug for detailed studies on the extent of the role of this enzyme in EtOH oxidation, a
hitherto controversial topic.

Speaking against this postulated mechanism

of PG action would be the fact that such

11

induction11 occurs very soon

after only a single dose of PG, which seems unlikely for enzyme induction
or act.ivation.

Actually, enzyme inhibition, unlike induction, could

occur much more rapidly and would not

r~quire

synthesis of new enzyme.

Moreover, EtOH turnover appeared to be unchanged after PG injection, arguing against an enhanced rate of EtOH catabolism.

Also, a large

increase in AcD blood level was seen after injection of AcD alone fol-
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lowing PG, imply:irg that a great part, i f not all, of the PG-induced AcD
elevation is due to an action of PG on AcD catabolism (Collins et al,
1974

).
Finally, aminotriazole, shown to inhibit hepatic catalase effec-

tively at the dose given (Margoliash and Novogrodsky, 1958), did not
lower the PG-potentiated AcD blood level (Collins et al 1974

).

This

again implies that activat:icn of catalase appeared to play no major role
in the action of PG.
It has been argued recently by Feytmans and Leighton (1973),
that the role of peroxidation of EtOH is minor in the rat after acute
administration, since inhibition of ADH
strong inhibition of EtOH oxidation.

activity by pyrazole effects a

However, these authors admit that

HzOz generation is the rate-limiting factor for peroxidation, while the
catalase content of the liver is in excess even to metabolize all the
EtOH the rat can oxidize.

Thus, a compound which generates large amounts

of Hz0 2 , as PG may, could increase the EtOH-oxidizing activity of catalase to a significant degree.

The lack of effect of aminotrlazole on the

PG-induced elevation of AcD may only mean that aminotriazole dosage was
not large enough to overcome the greatly stimulated catalase activity
created by PG-derived Hz0 2 •

Although aminotriazole 1 gm/kg has been

reported to cause 90-100% inhibition of hepatic catalase (Margoliash and
Novogrodsky, 1958), it may not do so under conditions of vigorously increased H2o2. levels.

This question should be examined experimentally,

possibly using higher dosage of aminotriazole

and measuring blood H2o2 •

(6) An inhibition of aldehyde catabolism, probably through ALDH,
may well be a significant mode of action of PG.

As such, it would ex-

plain the similarities in the effects on blood AcD and EtOH levels of
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both PG and the known ALDH inhibitor diethyldithiocarbamate ( Collins
et al, 1974).
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D.

EFFECT OF PYROGALLOL ON ALDEHYDE DEHYDROGENASE IN VITRO
The elevation by PG of AcD levels in EtOH- or AcD-treated rats

leads one to speculate that induction of EtOH catabolism or inhibition
of AcD catabolism may be occurring, as discussed.

Massive induction of

ADH by PG in the one-hour pre-EtOH period seems highly unlikely, especially since added cofactor (NAD) would probably be required for such an
occurrence.

The induction of the catalase system of EtOH catabolism,

perhaps by Hz0 2 generation, is unlikely, since pretreatment with the
catalase inhibitor aminotriazole was reported not to change the effect
of PG (Collins et al, 1974).

PG has been seen, though, to be ·a H2o2 -

generating compound (Heikkila, 1972), probably through the oxidation of
two of its hydroxyl groups.

This possibility requires examination,

possibly by measurement of PG-derived H2o2 injection on EtOH-derived
blood EtOH and AcD levels.

The difficulty in the latter scheme would

be in achieving high levels of H2o2 to simulate the proposed continuing
generation of HzOz of PG, without reaching lethal levels of HzOz that
might occur after a single large injection.
The inhibition of aldehyde reductase seems an unlikely mechanism
to be at w0rk, since the enzyme is found in low concentration in the
liver and appears to contribute insignificantly to the overall metabolism of aldehydes in the body (Tabakoff and Erwin, 1970). However, under
conditions of extremely high AcD levels such as those created by PG,
aldehyde reductase may be playing a much larger role than normal.

Pos-

sibly some of the EtOH levels seen after EtOH injection were derived
from the AcD reverting to its precursor.
increased EtOH levels (Collins
and AcD argues against this.

~

But the absence of appreciably

al, 1974) following injection of PG
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Inhibition of ALDH by PG was, in fact, seen in the in vitro
studies in this study.

Pyrogallol, similarly to propranolol (Duncan 1973),

reversibly inhibited ALDH, giving mixed inhibition with respect to both
aldehyde and NAD+cofactor.

The nature of en~yme inhibition by PG has

never been totally explicable, even in the well-known case of CA catabolism. Bacq (1936) originally attributed the NE pressor-potentiating
properties of PG to its antioxidant properties.

It is unlikely that anti-

oxidation is the means of inhibition of ALDH by PG, especially now that
it has been shown that the commercial antioxidant, propylgallate, had no
effect on ALDH activity.
The report by Crout (1961) on COrIT inhibition by PG stressed
that structural analogy, PG being a "double catechol 11 in effect, did not
explain the mixed competition that was observed.

In vitro, competitive

and partially non-competitive properties were seen.

Inhibition of COMI'

by PG preinjection lasted 30-60 minutes after a single injection of 200
mg/kg, or even longer after several smaller doses every half-hour for
several hours.
In our work, the millimolar concentrations calculated for the
ID50 values of pyrogallol and other compounds might be interpreted to
indicate only weak inhibition of ALDH.

However, millimolar levels of NAD

and propionaldehyde were required in these experiments to achieve detectable rates, since pH7.0, used to prevent PG oxidation, has been shown to
yield only one-fifth the activity seen at the optimal pH of 9.6-10.0
(Erwin and Dietrich, 1966).

Thus, the ID50 values for PG may be in the

micromolar rather than millimolar range had micromolar concentrations of
aldehyde been used, as in other studies (Duncan, 1973).

This may explain

the apparent discrepancy between the potent AcD-elevating effect of PG
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in vivo and its seemingly weaker ALDH inhibitory powe.r in vitro.
PG is known to affect other enzyme systems (Webb, 1966), although
the kinetics are usually not reported.

Dehydroshikimate reductase from

pea seedlings is inhibited by PG, as well as,by gallic and shikimic
acids.

Shikimic acid is non-aromatic but structurally similar to gallic

acid.

Shikimic acid showed no inhibition of ALDH in our study, possibly

because of the carboxyl group or perhaps because the ring is cyclohexyl
rather than phenyl, and the three hydroxyls are non-planar.
The enzyme histidine decarboxylase from guinea pig kidney can
also be inhibited by PG as well as by catechol, tyrosine, tryptophan,
and DOPA.

In that case, structural analogy seems to play very little

part, especially since tryptophan
group of the other compounds.

and indole

lack

even the hydroxyl

Finally, PG has been found to have a

slight inhibitory effect on lamb kidney D-amino acid oxidase at concentrations where catechol,hydroquinone, and similar compounds served as
stronger inhibitors.
PG has been reported to cause striking hepatotoxicity in animals
but the mechanism of this action is not quite clear (Webb, 1966)
Very little else is known of the biochemical pharmacology of PG,
but all facts should be recognized if ever therapeutic uses of this drug
are proposed.

The LD50 was calculated to be 566 mg/kg in normal mice,

and 490 mg/kg in hyperthyroid mice (Webb, 1966).

Since thyroid hormones

have been found to be COMT inhibitors in vitro (D'Iorio, 1963), perhaps
their increased levels in hyperthyroidism cause an inhibition of PG
methylation by COMT, thus increasing PG half-life and toxicity.

PG is

also known to act as a mitotic inhibitor of oligochaete cleavage, the
mechanism of which is unclear, but the same property belongs to others
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with quinone structures.

In fact, many of the physiobiochemical effects

of PG have not been studied directly but can only be inferred from known
properties of quinones, benzoquinone (called hydroquinone in reduced
form) being the most commonly tested.
The methemoglobinemia induced by quinones significantly in vitro
is insignificant in vivo, implying that erythrocytes can reduce quinones
effectively (Webb, 1966).

Apparently, then, the darkened blood observed

after PG injection of rats in these experiments was due to products of
PG or to some mechanismcther than methemoglobinemia.
Oxidative phosphorylation is inhibited by various quinones, but
little evidence is available as to whether electron shunts, phosphorus
transfer, quinone displacement, or sulfhydryl reaction is the mechanism
responsible.

Although the vitamins K belong to the quinone family, none

of the PG-related quinones have been seen to inhibit vitamin K synthesis
(Webb, 1966).

Such bleeding difficulties, even had they been inductible

by PG, would have had little bearing on the short-term experiments done
in this study.
In animals, the CNS stimulation by quinones is followed by
depression of the CNS and of respiration (Webb, 1966).

This resembles

the effect of PG, that of pressor response soon followed by tachyphylaxis
(Wylie~

al, 1960).

It is possible that some of the physiologic

darkening of the blood in rats treated with PG was due to cyanosis secondary to respiratory depression.

It was noted that the rate of respira-

tion seemed to be increased, but quantitation of the respiratory depth
was not done.

Unlike animals, humans who have overdosed with catechol,

hydroquinone, and others, show only depression with no initial stimulation.

This depression has been found not to be the result of asphyxia,
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methemoglobinemia, or hypoglycemia (Webb, 1966).

As can be seen, much

work on the pharmacology of the quinones and of PG in particular needs
to be perfonned.
The compound RO 4-4602, very important in Parkinson's disease
therapy as a decarboxylase inhibitor and also shown to be a COM!' inhibitor (Baldessarini, 1972), has now been shown to be an in vitro ALDH
inhibitor of approximately equivalent strength to pyrogallol.

The

presence of the gem-trihydroxybenzene nucleus of both drugs may account
for their similar actions.

The lesser AcD-potentiation in vivo caused

by RO 4-4602 compared to PG (unpublished results), may be due .to more
rapid catabolism, excretion, or distribution of RO 4-4602, due to the
serylhydrazine residue.

RO 4-4602 was one of only three compounds that

affected both AcD levels in vivo and ALDH activity in vitro, the others
being pyrogallol and diethyldithiocarbamate.

Several compounds had in

vitro but not in vivo effects at the concentrations tested, including
hydroquinone, 3-methoxycatechol, and gallic acid, while the in vitro
inhibitor 1,2,4-trihydroxybenzene, was not tested in vivo, but 6-hydroxyDA was tested (The 1,2,4-trihydroxybenzene moiety is present) and
caused no increases in blood AcD in EtOH intoxicated rats (Collins
1974).

~

al,

Interestingly, all in vivo AcD-potentiators were found to have

ALDH inhibitory powers in vitro (Table 9). However, the order of potency in vivo did not correspond to the in vitro strengths.
From the results of these experiments, the PG-induced enhancement of pressor responses to CAs may now be thought of as arising from two
possible actions of PG: COMT inhibition and ALDH inhibition. Increased
levels of biogenic amine-derived aldehydes may be induced by PG administration.

It has been suggested that these aldehydes have pharmacol-
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ogic properties of their own (Sabelli and Giardina, 1971; Barondes, 1962)
through (a) release of stored amines, (b) shifts in metabolic pathways,
(c) incorporation into storage vesicles, (d) condensation with endogenous
amines.

Thus, some of the pharmacologic actions of PG may be mediated

by certain endogenous aldehydes.
It is possible that a non-toxic PG containing compound similar to
RO 4-4602 could be employed by clinical investigators as substitutes for
disulfiram (Antabuse) therapy in alcoholics.

Various toxic manifestations

of Antabuse treatment (Fox, 1973), including death, may be reduced by
using a different inhibitor of ALDH.
Another likely use for PG is in experiments where condensation
products of aldehydes and CAs (e.g. tetrahydroisoquinolines or TIQs) are
sought after EtOH administration.

By maximizing levels of TIQ precur-

sors, e.g. Norepinephrine and AcD, while simultaneously blocking 0-methylation of the TIQs, levels of TIQs in tissues may be raised to increase
the ease of their detection.

In fact, such experiments utilizing the

twin actions of PG have already been reported (Collins and Bigdeli, 1974).
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CHRONIC ALCOHOL DRINKING MODELS
1. MOUSE EXPERIMENTS
The intoxicating effects of the EtOH-Metrecal protocol on male

mice indicated that these animals appeared more susceptible to the effects of EtOH than were female mice or male rabbits.

The withdrawal

effects, however, were less marked than were those seen by Freun:l.These
discrepancies might be attributable to strain or sex differences, or to
specific factors associated with feeding.
First of all, clogging of the metal tubes, through

which mice

drank from inverted glass bottles, appeared to be a factor.The .sediment
from Metrecal, although prepared fresh and shaken well, often clogged
the tube and starved the animals, in effect, until the next feeding the
following morning.

Examination of the bottles at 12 A.M. to 2 A.M. on

various nights still did not prevent this occurrences.
may not have drunk as

Thus, animals

much as they would have without clogging.

did not report such a complication in his study.

Freund

This problem may have

led to some of the deaths seen during EtOH drinking, especially in mice
that were found dead with hind limbs extended, which according to
Freund, denotes death during convulsion.

Use of larger bore feeding

tubes did not decrease the clogging, even in our rabbit experiment, so
open pottery crocks were used with the rabbits.
A second factor contributing to our lack of success with intoxication and withdrawal signs in mice may well be that we, as well as .
Freund, were observing effects of Metrecal toxicity or of malnutrition.
This factor has been examined by Mendelson.

Data leading to this

conclusion include the facts that (a) mice were dying during the weight
reduction, (b) more mice died during EtOH drinking, possibly due to the
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combined effects of weight reduction and EtOH, (c) EtOH drinkers continued to lose weight while the isocaloric sucrose group gained almost 20%
more than the EtOH group, and (d) EtOH drinkers consumed only 50% of the
volume, and therefore of the calories, of their sucrose counterparts.
These data lead to the conclusions that (a) drastic weight reduction
should be avoided, (b) pair-fed controls are required to rule out caloric
discrepancies, and (c) some of the behavioral effects attributed to EtOH
in our experiment may be due to toxicity of Metrecal or to malnutrition,
as has been suggested by Mendelson (1971).

r
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2. RABBIT EXPERIMENTS
Although the number of rabbits used (3 ethanol, 3 sucrose) is
limited, several observations can be made regarding the feasibility of
this ethanol-Metrecal diet in rabbits.
Four factors in the design of this experiment

~re

worthy of note:

(1) The choice of either alcohol drinking or starvation, rather than
force-feeding, was implemented.

This may allow various systems within

the animal to regulate its alcohol and caloric intakes.
alcoholic pattern is more closely approximated.

Thus, the human

Further, the occurrence

of gastrointestinal ulcerations and other results of force-feeding may be
avoided, but the question of alcohol preference was begged in this protocol.
(2) Pair-fed controls were used to eliminate the effects of malnutrition
often seen from depression of appetite by ethanol.

The importance of

pair-feeding is demonstrated in Freund's report on the mouse-Metrecal
model, wherein animals on the ad lib ethanol diet drank less than one-half
the amount of fluid as those drinking isocaloric sucrose ad lib (Table 12).
This fact, on top of the 20% weight reduction effected in Freund's mouse
experiments, possibly contributed to the intoxication and withdrawal
effects, even though, as Freund notes, the clinical symptomatology induced
by extreme starvation is quite different from the ethanol withdrawal syndrome.

In our study, ethanol and sucrose groups were control-fed not

only for caloric concentrations, but for total daily caloric in-take as well.
(3) A possible weak point in our study may be the massive concentration
of ethanol attained in the experimental diet.

The gradual increase from

6% to 20% v/tv ethanol was instituted because no significant gross
intoxication was observed at the lower ethanol concentrations.

It is

still possible that behavioral alterations did occur at night while the
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animals were not watched.

However, the ability to catabolize ethanol

and acetaldehyde seemed to be accelerated in ail ethanol-treated animals
as evidenced by the cyclical blood level curves of these compounds,
despite increasing intake, at all but the two highest concentrations of
diet ethanol (Fig. 9).
intoxication.

Even these high conc~ntrations failed to produce

Apparently, enhanced EtOH metabolism and/or possible ad-

aptation of the nervous system may have prevented gross behavioral changes.
(4) Large pottery bowls were used as food containers rather than glass
bottles or cylinders with steel drinking tubes.

The latter, in our hands,

had a great tendency to clog up due to the sedimentation of particles
from the chocolate Metrecal itself.

In the experiments with mice, this

clogging may have resulted in several deaths from either starvation or
alcohol withdrawal.

The large surface area of the pottery bowls was not

seen to increase evaporation of ethanol, since less than 2% evaporation
of ethanol in 24 hours was observed when the supernatant of the 500 xg
centrifugate was assayed by gas chromatography.
The pathological changes in the animals brought up the possibility of nutritional deficiencies and/or toxicity of Metrecal itself. The
lack of normal weight gain and the loss of body hair throughout the experimental period occurred in both the ethanol and sucrose groups.

This

points to the lack of proper nutrients for rabbits in this diet protocol.
The severely fatty livers seen only in the ethanol group indicates the role of alcohol, and not of malnutrition, in producing such
fatty change.

Ruebner et al (1972) also found that substitution by

isocaloric carbohydrates for ethanol did not reproduce the fatty livers
in monkeys fed Freund's diet at a diet ethanol concentration of 7.9%

r
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v/tv.

In addition, choline supplements to the diet in Ruebner's work

did not reverse the fatty changes, suggesting that these changes are not
due to the lack of lipotropic factors or to dietary imbalance, but to
EtOH itself.
The single death that occurred four days before the end of the
study was that of a sucrose control animal.

This further implicates the

lack of proper nutrients for rabbits in this diet, especially when daily
volumes are limited by pair-feeding.

The liver of this dead animal

appeared no different from those of the other animals in the sucrose
group, indicating that the cause of death was not reflected in the cytoarchitecture of the liver by light microscopy.

It is possible, though,

that further deaths in both experimental and control animals may have
occurred had the length of the study been extended. It is also possible
that EtOH served some protective function in animals imbibing it, thus
prolonging their lives.

It was not clear whether the single death

resulted from:
(1) Prolonged nutritional deficiency from the composition or amount of
the diet;
(2) Possible hepatotoxicity of Metrecal as suggested by Mendelson, which
was not noticeable by light microscopy· in our study, but may still be
contributory;
(3) An illness unrelated to diet;
(4) The last factor, the absence of bulk, may be underscored by citing
the percent fiber found in Purina Lab Chows for mice (3.8%) versus that
for rabbits (14.6%) (Purina, 1972).

The lack of fiber in a liquid diet

may lead to abnormalities of digestive processes upon which proper
nutrition depends.
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Ethanol and acetaldehyde blood levels in rabbits were hard to
compare to those of other studies, primarily because of the differences
in dose, species, age, sex, route of aministration, and other factors.
The blood levels in our studies usually were in the range of 0-100 mg%
EtOH and 0-9 pg/ml AcD.

Majchrowicz (1973), feeding EtOH to rats by

intragastric intubation for up to eight days, showed that blood EtOH and
AcD concentrations ranged frcm 100-500 mg% and l-3pg/ml, respectively.
Freund's mice reached blood levels of EtOH of at least 400 mg% while
drinking EtOH-Metrecal ad lib for five days.

Very few EtOH metabolism

experiments with rabbits, however,.have been reported.

Duritz and Truitt

(1966) observed peak blood EtOH and AcD levels of 380 mg% and 4f1g/ml,
respectively, after acute EtOH injection (4.0 g/kg i.v.) in rabbits.
Both the rate of alcohol metabolism and the range of blood alcohol
concentrations were lower in rabbits than in rats and mice in a study
cited by Israel and Mardones (1971).

These authors calculated rabbit

EtOH metabolism to be less than one-third that of rats and the blood
alcohol was found to range from 30-100 mg% under conditions that gave
rats levels of 0-300 mg%.
Blood AcD concentration seemed to be related to blood EtOH levels
in our rabbits, but other investigators (Mello and Mendelson, 1970) found
no dose or dose-time relationship between blood EtOH and blood AcD, and
also saw that mean blood AcD concentrations were relatively constant
through all dose ranges of EtOH, possibly due to rapid induction of ALDH.
Lack of gross intoxication in our animals, even with high blood
EtOH levels, may involve enhanced EtOH metabolism by the liver or by the
nervous system.

Raskin and Sokoloff (1972) have demonstrated a minute

amount of alcohol dehydrogenase in the rat brain which undergoes an

l
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adaptive increase in its activity during chronic EtOH (
ingestion . . In human

20 days)

alcoholics studied by Mello and Mendelson

(1970),

blood alcohol level was rarely found to be an adequate predictor of
behavior~

possibly inferring nervous system adaptation.

Relatively similar blood AcD and EtOH levels despite increasing
EtOH consumption may be related to an increase in the rate of EtOH metabolism, although this effect is still controversial, as indicated in a
review by Hawkins and Kalant (1972).

These au tho rs point to two proces-

ses that may be involved in the effect of prolonged EtOH intake on the
levels of liver alcohol dehydrogenase: an

adaptive process involving a

specific induction of ADH, and a non-specific decrease of enzyme levels
as a manifestation of depressed protein synthesis resulting from liver
impairment.
The three-month duration of this experiment may contribute to
some of our findings, since the age of the animal is known to influence
the blood EtOH concentration and the rate of its disappearance.

These

differences apparently are not due to altered liver ADH activity, but
may be caused by

age-dependent changes that may alter the compartmental-

ization (e.g. body fat) NAD/NADH 2 ratios, or rate of metabolism of EtOH
by processes other than ADH (Hollstedtand Rydberg, 1970).

The very high

levels of EtOH and AcD seen near the end of the experiment, however, may
well be due to general debilitation caused by prolonged malnutrition.
Further, malnutrition states, such as ascorbic acid deficiency, are known
to themselves contribute to changes in A.DH and NAD/NADH
et al, 1972)

2

ratios (O'Keane
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F.

SUMMARY
These studies have uncovered the important role of PG as a dual

enzyme inhibitor, favoring catecholamine-derived isoquinoline formation
in in vivo studies.

The first report of gas chromatographic evidence of

isoquinoline biosynthesis after ethanol intoxication (Collins and Bigdeli,
1974) has recently emerged.

These authors utilized the effects of PG

revealed in the present studies.
Pyrogallol can now be postulated to enhance isoquinoline levels
in vivo through at least three biochemical mechanisms, two of which were
demonstrated for the first time in these studies:
(1) The oxidation of acetaldehyde via aldehyde dehydrogenase is
inhibited, thus maximizing concentrations of one isoquinoline precursor.
(2) The 0-methylation and possibly inactivation of isoquinolines
are decreased.
(3) Combined with the well-known inhibition by pyrogallol of the
catechol 0-methyltransferase degradation of norepinephrine and dopamine,
these first two effects lead to elevated isoquinoline levels and maximal
possibility of detection.
Compounds structurally related to PG were found to inhibit
aldehyde dehydrogenase in vitro _and elevate ethanol derived acetaldehyde
levels in vivo, properties which may lend these drugs to clinical application as disulfirarn~lile deterrents in alcoholics.
Animald models of chronic alcoholism using a liquid (Metrecal)
diet were anernpted.

This protocol pro.duced intoxication and slight

withdrawal symptoms in mice.

Rabbits, despite developing elevated blood·

acetaldehyde and ethanol concentrations, displayed virtually no gross

90
intoxication while demonstrating fatty liver changes.

Malnutritional

aspects of this diet were possible.factors contributing to the pathologies
seen.

r
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TABLE 1

Composition of liquid diet*

EtOH (95%)

EtOH

6

Sucrose __

*Freund, 1969.

35

Metrecal

61

65

61

65

Sucrose 87% w/tv

9

35

Water added
v/tv

cal/ml diet

33

0.9

30

0.9

Diet used in this study with mice and initially with
rabbits.

r
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TABLE 2

Maximal Stages of Intoxication and Withdrawal reached
in mice

No. mice
Freund

Intoxication

J.R.

1. ataxic, but rapid gait

12/48

0/10

2. between 1 and 3

25/48

5/10

3. coma, no righting reflex

11/48

5/10

1. overactivity, tremors

6/28

0/10

2. tail-beating, tail-to-nose,
retropulsion, broad gait,
stereotypy

2/28

3/10

3. tonic-clonic convulsion

1/28

6/10

4. deatr during convulsion

0/28

1/10

Withdrawal

J.R.= results of present study
Freund= results of G. Freund (1969)
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TABLE 3

Reaction times of NE and EPl with aldehydes to form TIQs,
determined by iodochrome monitoring

Reaction time (min)

HCHO
NE

20

5

EPl

35

7

r
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TABLE 4
Rf values for NE an<l NE-derived TIQs by thin-layer
chromatography in two solvent systems

System A

System B

NE

0.40

0.22

NM

0.46

0.31

TIQ I

0.33

0.29

6-0-Me-TIQ I

0.43

0.26

TIQ I I

0.18

0.21

6-0-Me-TIQ I I

0.28

0.27

System A: sec-butanol:formic acid: water (15:3:2),
Adsorbosil-1 TLC plate
System B: methanol:n-butanol:benzene: water (40:30:20:10),
cellulose MN 300 plate

,......-

--"'~~

TABLE 5
Effect of Pyrogallol on the 0-methylation of Noradrenaline and two tetrahydroisoquinoline
derivatives in rat brain and liver homogenates
Liver

~rain

% 0-Methylation*

3H-Compound

Saline

· ··PG

··

% Inhib. due

% 0-Methylation*

to PG

Saline

PG

+

% Inhib. due
to PG

NE

(5)~'c*

33.6 :!:" 4.6a

15 .5 +- 3.0

53.9

35.3 :!:" 4.6b,c

17.6 - 3.4

50.2

TIQ I

(8)

21.5 :!:" 6.la

2.0 +- 1.0

90.7

78.2

± 8.3b,d

31.0 +
- 4.6

60.4

29.3 +
- 4.5

7.9 +- 3.2

73.l

58.l

"t 4.5c,d

6.2 +- 5.1

89.4

TIQ II (8)

* Per cent of added substrate that was 0-methylated, out of total radioactivity, corrected for
recovery, ( recovery= 70 ± 5 per cent). Results expressed as mean: S.D.
**Number of determinations for each saline and each PG experiment in parentheses.
Statistical significance by student's unpaired t-test:
a - p < 0.005
b, c,d -

p <

0.001

\0

\JI

-,
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TABLE 6
Effect of PG on EtOH-derived AcD and EtOH blood levels (pg/ml)
Saline
AcDa

Time(min)

1.2 +- 0.3

1200 t 300

2.0 +- 0.8

1000 ~ 300

60

+
2.6 - 0.5

1600

330

4.8 +- 1.2

1900 : 550

120

2.0 +- 0.4

1700

t
t

400

4.1 +- 1.6

1900

":!:"

470

1200 : 380

3.6 +- 1.2

1300

t

410

650 : 220

+
1.9 - 0.4

600

':!_-

280

300 ~ 200

+
0.5 - 0.3

450 :- 210

270

+
1.0 - 0.2
+
0.3 - 0.1

360

+
0.1 - 0.1

Each figure represents mean
i.p.)

b

EtOHb

30

180

a p

PG

AcDa

EtOHb

":!:"

S.D. of 4 rats following PG (250 mg/kg i.p.) 1 hour before EtOH (2.0 g/kg

< 0.05, PG compared to saline, at 60, 120, 180 and 270 min.

N.S. at any time, PG-compared to saline.

Student's unpaired t-test.

\0
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TABLE 7

Reversibility and deletion controls in studies on the effect of
PG on Al.DH activity

Pre-Incubation with
PG

Conditions
(1)

NAD, Enz, Prop.

(2)

(1) plus PG 3

Activity
12.5

3

6.3

(3)

II

II

"

5

6.3

(4)

"

II

II

10

6.3

(5)

II

"

"

15

6.3

(6)

NAD,

(7)

NAD, Prop.

0.2

(8)

Enz., Prop.

o.o

(9)

NAD, Enz., PG

3

0.3

(10)

NAD, Prop., PG

3

0.1

(11)

Enz • , Prop • , PG

3

o.o

(12)

PG-Enz.,aliquot4

3

6.3

0.5

~nz.

1

moles NADH/min/mg protein xlo- 11

2

Enz.= enzyme, Prop.= propionaldehyde

3

PG = pyrogallol, 10-4 M

4

Reversibility experiment (see text)

r
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TABLE 8
Effect of pyrogallol and related compounds on in vitro
activity of rat liver mitochondrial aldehyde dehydrogenase
COMPOUND

M x 10-4

Pyrogallol (PG)

1,2,4-Trihydroxybenzene

ACTIVITY

% INHIBITION

0
0.5
5.0
10.0

12.5
11. 7
8.8
6.3

0
6.4
27.0
49.5

0.5
5.0
10.0

7.7
6.3

s.o

38.5
49.5
60.0

Hydroquinone

0.5
5.0
10.0

9.3
7.3
5.8

26.2
41.9
54.1

RO 4-4602

0.5
5.0
10.0

11.8
8.0
6.5

5.4
36.8
46.0

Diethyldithiocarbamate (DDC)

0.5
5.0
10.0

11.6
9.2
8.3

6.8
26.7
33.3

3-Methoxycatechol

0.5
5.0
10.0

12.5
10.3
8.6

0
17 .2
31.4

Gallic Acid

0.5
5.0
10.0

12.5
12.5
10.6

0
0
15.6

2,3-Dimethoxyphenol

0.5
5.0
10.0

12.5
12.0
11.6

0
4.3
6.9

Propylgallate

0.5
5.0
10.0

12.5

0

0.5
5.0
10.0

d,1-Shikimic Acid

12~5

0

11. 7

6.2

12.5
12.5
12.l

0
0
3.4
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TABLE 8 (continued)

M x 10- 4

ACTIVITY

% INHIBITION

3,4-Dihydroxytoluene

0.5
5.0
10.0

12.5
12.5
12.5

0
0
0

Tetrahydroxyquinone

0.5
5.0
10.0

12.5
12.5
12.5

0
0
0
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TABLE 9
Comparison of in vitro ALDH inhibition and in vivo potentiation of EtOH- derived AcD blood levels.

Category

Compound

In vitro

In vivo*

1

PG

+

+

2

DDC

+

+

1,3

RO 4-4602

+

+

4

1,2,4-trihydroxybenzene

+

**

4

Hydroquinone

+

0

5

3-methoxy-Catechol

+

0

5

2,3-dimethoxy phenol

0

0

4

Gallic acid

0

0

*

Collins et al, 1974.

** Lethal at dose used for other compounds.
In vitro= + = inhibits ALDH over 15% at 5 x 10-4 M.
In vivo=

+ = increases blood AcD post-injection of EtOH (3g/kg)
compared to saline.

Categories:
l= COMT inhibitor; 2=ALDH inhibitor;

3= DOPA decarboxylase

inhibitor; 4= similar structure to PG; 5= product of COMT action on PG
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TABLE 10
Weight change of rabbits drinking Metrecal diets

DIET

EtOH

% change from initial

weight

Average Group
change

+ 5

-0.67 ~ 2.94

II

-10

II

+ 3

Sucrose

+ 7

II

+ 7

II

+ 5

Lab chow

+73

+6.33 +- 0.94

+73.0

+
- 0.00

r
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TABLE 11
Animal deaths during chronic alcohol experiments

Mice

*

Weight-reduction

5/180

EtOH-drinking

8/ 80*

Withdrawal

0/ 28

Sucrose-drinking

0/ 20

Rabbits

0/3

1/3

3 died with limbs extended, possibly denoting convulsions.
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TABLE 12
Weight change in mice during Metrecal diets

{with Metrecal}

Diet

Sucrose-(n=29)
EtOH -

(n=42)

fa

change from initial weight* {Ave.2

+ 14.6 +- 4.2
4.4 + 2.9

* following 9 days of weight reduction
p

< 0.01, student's unpaired t-test

..

r
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TABLE 13
Daily volume of Metrecal diet consumed ad. lih. by mice

Volume, ml (aver., 5 days)

Diet
Sucrose (n=29)

EtOH

p

16.3

(n=42)

<

0.01,

8.2

+ 2.1
t

3.7

Student's unpaired t-test.

Values expressed as average± S.D.

r
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TABLE 14
EtOH consumption pattern of rabbits

% EtOH (v/v)

% total calories

from EtOH

Days at
this level

EtOH consumption,
ml (average, n=3)

6.0

35

12

15.8

7.5

39

4

21.9

10.0

46

19

26.7

12.5

54

10

25.8

15.0

59

10

25.0

17.5

63

6

27.1

20.0

71

19

29.1

r
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TABLE 15
Physical effects of liquid diet on rabbits

Hair loss

Death

Weight change %*

EtOH

2/3

0/3

- 1

Sucrose

2/3

1/3

+ 7

Lab Chow

0/1

0/1

+ 73

*

Per cent of weight at start of diet administration.
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OH
0II

CH 3 CH

>HO
CH 3

TIQ I

+

HO

H

AcD

OH
HO

HO

OH

NE
0II

HCH

HCHO

HO

>HO

H

TIQ II

FIG. 1. Condensation of norepinephrine with aldehydes to form
tetrahydroisoquinoline alkaloids.
NE=norepinephrine, AcD=acetaldehyde,
TIQ=l,2,3,4-tetrahydroisoquinoline.

HCHO=formaldehyde,
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RELATIVE RETENTION TIMES

FIG. 2.

Gas chromatogram of air, water (HzO), acetaldehyde (AcD),
ethanol (EtOH) and acetone, using Porapak Q-S column in
Varian 2100 gas chromatograph.
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NE

T IQ 11
(HCHO)

FIG. 3.

TIQ I
(AcD)

Metabolism of TIQs in rat liver homogenate.

Results expressed in terms of percent non-catechol CO-methylated)
products formed, out of total recovered radioactivity.
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D.

NE

TIQ 11
(HCHO)

FIG. 4.

TIQ I
(AcD)

Metabolism of TIQs in rat brain homogenate

Results expressed in terms of percent non-catechol (O-methylated)
products formed, out of total recovered radioactivity.
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FIG. 5.

Calibration curve for EtOH and AcD in whole blood determined
by the micromethod of Coldwell et al (1971).

Peak heights expressed in divisions on recording paper (n=4 per point)
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•c

0
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.a
0

•

.a

c

I
B
Time

FIG. 6.

--+

Representative spectrophotometric recording in aldehyde
dehydrogenase assay.

S= substrate alone added; S + I = substrate plus inhibitor;
I= inhibitor alone added; B= blank control, no substrate or inhibitor
added. Absorbance is expressed in optical density units at 340 run.
Time scale is 2 min. Total.
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FIG. 7.
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4.0

3.0
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e.o

Double reciprocal plot of the inhibition of rat liver mitochondrial ALDH by PG with respect to NAD cofactor •

PG concentrations:

8,

none;

•
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.._ ,

500
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FIG. 8.
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3.0

Double reciprocal plot of the inhibition of rat liver mitochondrial ALDH by PG, with respect to the substrate propionaldehyde.

PG concentrations: • , none:
PROP= propionaldehyde.

• , 100 FM;

.A. , 500

pM.
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A 40
TIMI!
(Daya)

A

80

Ethanol and acetaldehyde blood levels and daily ethanol
consumption in a representative rabbit drinking Metrecal/
ethanol.

/\ indicates increased ethanol concentration in diet
(6.0, 7.5, 10.0, 12.5, 15.0, 17.5, and 20.0 % v/v, respectively).
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PG

OH

!-

OH

COM T >

NM

NE

PG

!-

OH
HO

COMT>
H

HO
R

4,6,7-0H-TIQ

OH
CH 3 0
H

HO
R

6-0-METHVL
4 ' 7-0H-TIQ
.

FIG. 10. Analogous metabolism by COMT of NE and NE-derived TIQs,
inhibitable by PG.
R= H or CH3 ; NE= norepinephrine; NM= normetanephrine; COMT= catechol
0-methyltransferase; PG= pyrogallol; TIQ= 1,2,3,4-tetrahydroisoquinoline.
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Time (min.)

FIG. 11.

Effect of pre-injection of PG or saline on AcD disappearance
in rat liver homogenate.

Doses: PG 250 mg/kg or saline 0.9%, 1 ml i.p. 1 hr. pre-sacrifice.
Homogenate: 1 ml rat liver homogenate 1:1 in pH 7 pyrophosphate buffer.
AcD 0.33 mM and NAD 0.33 mM added.
Peak heights expressed in cm. as mean± S.D. (n=3).
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HOY
HO
t,2,4-Trlhydroxybenzene
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Structures of PG and related compounds tested for effect on
in vitro activity of rat liver mitochondrial ALDH.
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FIG. 13.

Liver section of rabbit after 80 days of EtOH/Metrecal diet,
showing abundant fat vacuoles.
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FIG. 14.

Liver section of rabbit after 80 days of Sucrose/Metrecal
diet, showing relatively normal cell structure with slight
fatty changes.
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ABBREVIATIONS

AcD

acetaldehyde

ADH

alcohol dehydrogenase

AH

aluminum hydroxide

ALDH

aldehyde dehydrogenase

ATP

adenosine triphosphate

CA

catecholamine

CAMP

cyclic adenosine 3' ,5'-monophosphate

COMT

catechol 0-methyltransferase

DA

dopamine

DBH

dopamine beta-hydroxylase

DDC

diethyldithiocarbamate

DOPA

dihydroxyphenylalanine

DS

disulfiram

E

epinephrine

EtOH

ethanol

gm

gram

HCHO

formaldehyde

hr

hour

5HT

serotonin (5-hydroxytryptamine)

K

potassium

kg

kilogram

MAO

monoamine oxidase

Mg

magnesium

mg

milligram

min

minute
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ABBREVIATIONS (continued)

ml

milliliter

Na

sodium

NE

norepinephrine

0-Me-TIQ

6-0-methylated form of corresponding TIQ

PG

pyrogallol

PNMT

phenylethanolamine N-methyltransferase

SAM

S-adenosylmethionine

TH

tyrosine hydroxylase

THP

tetrahydropapaveroline

TIQ

tetrahydroisoquinoline

TIQ I

l-methyl-4,6,7-trihydroxy-TIQ

TIQ II

4,6,7-trihydroxy-TIQ
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